Study Title: 
Sponsor: 
INDNumber: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
Gilead Medical 
Monitor: 
Protocol Version/Date: ~ GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 2, Randomized , Double-Blind , Placebo-Contmlled Study 
Evaluating the Safety, Tolerability , and Efficacy of GS-9674 in 
Subjects with Nonalcoholic Steatohepatitis (NASH) 
Gilead Sciences , Inc. 
333 Lakeside Drive 
Foster City, CA 94404 
U.S.A. 
127960 
20 16-0024 96-10 
TBD 
Nonalcoholic steatohepatitis (NASH) 
GS-US-402-1852 
Name: 
Telephone: 
Fax: 
Email: 
Original: G-~ ~hen Djedjos, M.D. PPD 
PPD 
t"'t"'U 
28 June 2016 
CONFIDENTIALITY STATEMENT 
The inf01mation contained in this document , particularly unpublished data, is the property or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator , 
potential investigator , or consultant , for review by you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee. The inf01mation is only to be used by you in 
connection with authorized clinical studies of the investigational dmg described in the protocol. 
You will not disclose any of the inf01mation to others without written authorization from 
Gilead Sciences , Inc., except to the extent necessaty to obtain inf01med consent from those 
persons to whom the dmg may be administered. 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 2 28June 2016TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ................................................................................................
........................................ 5
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 12
1. INTRODUCTION .............................................................................................................................................. 16
1.1. Background ............................................................................................................................................ 16
1.1.1. GS-9674 General Information .............................................................................................. 17
1.1.2. Nonclinical Toxicology ........................................................................................................ 17
1.1.3. Nonclinical Pharmacology ................................................................................................... 18
1.1.4. Nonclinical Pharmacokinetics .............................................................................................. 19
1.1.5. Clinica l Trials of GS -9674 ................................................................................................... 20
1.2. Rationale for This Study ........................................................................................................................ 24
1.3. Risk/Benefit Assessment for the Study .................................................................................................. 26
1.4. Com pliance ............................................................................................................................................ 26
2. OBJECTIVES ..................................................................................................................................................... 27
3. STUDY DESIGN ...............................................................
................................................................................. 28
3.1. Study Design .......................................................................................................................................... 28
3.2. Treatment Plan and Regimen ................................................................................................................. 28
3.3. Biomarker Testing .................................................................................................................................. 29
3.3.1. Biomarker Samples to Address the Study Objectives .......................................................... 29
3.3.2. Biomarker Samples for Optional Future Research ............................................................... 29
3.3.3. Biomarker Samples for Optional Genomic Research ........................................................... 29
4. SUBJECT POPULATION .................................................................................................................................. 31
4.1. Number of Subjects and Subject Selection ............................................................................................ 31
4.2. Inclusion Criteria .................................................................................................................................... 31
4.3. Exclus ion Criteria ................................................................................................................................... 32
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 35
5.1. Randomization, Blinding and Treatment Codes .................................................................................... 35
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 35
5.2. Description and Handling of GS -9674 and PTM GS -9674 .................................................................... 35
5.2.1. Form ulation .......................................................................................................................... 35
5.2.2. Packaging and Labeling ....................................................................................................... 36
5.2.3. Storage and Handling ........................................................................................................... 36
5.3. Dosage and Administration of GS -9674/ PTM GS -9674 ....................................................................... 36
5.4. Prior and Concomitant Medications ....................................................................................................... 37
5.5. Prohibited Medications ...............................................................
........................................................... 37
5.6. Accountability for GS -9674/ PTM GS -9674 ......................................................................................... 39
5.6.1. Investigational Medicinal Product Return or Disposal ......................................................... 39
6. STUDY PROCEDURES .................................................................................................................................... 40
6.1. Subject Enrollment and Treatment Assignment ..................................................................................... 40
6.2. Pretreatment Assessments –Screening Visit ......................................................................................... 40
6.3. Baseline/Day 1 Randomization and Assessments .................................................................................. 42
6.4. Treatment Assessments .......................................................................................................................... 43
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 3 28June 20166.4.1. Week 1 ................................................................................................................................. 43
6.4.2. Week 4 Visit ......................................................................................................................... 44
6.4.3. Week 8, 16, and 20 Visits ..................................................................................................... 45
6.4.4. Week 12 Visit ....................................................................................................................... 46
6.4.5. Week 24 Visit ....................................................................................................................... 47
6.4.6. Unscheduled Visits ............................................................................................................... 48
6.5. Follow -Up Visit ..................................................................................................................................... 49
6.6. Assessments for Premature Discontinuation from Study ....................................................................... 49
6.7. Criteria for Discontinuation of Study Treatment .................................................................................... 50
6.8. PK and PD Substudy Visits .................................................................................................................... 50
6.9. Description of Assessments ................................................................................................................... 51
6.9.1. Clinical Laboratory Analytes ............................................................................................... 51
6.9.2. Medical History .................................................................................................................... 52
6.9.3. Physical Examinatio n........................................................................................................... 52
6.9.4. Quality of Life (QoL) Assessments ...................................................................................... 52
6.9.5. Electrocardiogram ................................................................................................................ 53
6.9.6. FibroScan®................................................................
........................................................... 53
6.9.7. MRE and MRI -PDFF ........................................................................................................... 53
6.10. End of Study Definition ......................................................................................................................... 54
6.11. Post Study Care ...................................................................................................................................... 54
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 55
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 55
7.1.1. Adverse Events ..................................................................................................................... 55
7.1.2. Serious Adverse Events ........................................................................................................ 55
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 56
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 56
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 56
7.2.2. Assessment of Severity ........................................................................................................ 57
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead ...............................................................
........................................................ 57
7.4. Gilead Reporting Requirements ............................................................................................................. 59
7.5. Toxicity Management ............................................................................................................................ 59
7.6. Special Situations Reports ...................................................................................................................... 62
7.6.1. Definitions of Special Situations .......................................................................................... 62
7.6.2. Instructions for Reporting Special Situations ...............................................................
........ 62
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 64
8.1. Analysis Objectives and Endpoints ........................................................................................................ 64
8.1.1. Analysis Objectives .............................................................................................................. 64
8.1.2. Primary Endpoint ................................................................................................................. 64
8.1.3. Exploratory Efficacy Endpoints ........................................................................................... 65
8.2. Analysis Conventions ............................................................................................................................. 65
8.2.1. Analysis Sets ........................................................................................................................ 65
8.2.2. Interim Analysis ................................................................................................................... 67
8.3. Data Handling Conventions ................................................................................................................... 67
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 67
8.5. Efficacy Analysis ................................................................................................................................... 67
8.6. Safety Analysis ....................................................................................................................................... 68
8.6.1. Extent of Exposure ............................................................................................................... 68
8.6.2. Adverse Events ..................................................................................................................... 68
8.6.3. Laboratory Evaluations ........................................................................................................ 68
8.6.4. Other Safety Evaluations ...................................................................................................... 69
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 4 28June 20168.7. Pharm acokinetic Analysis ...................................................................................................................... 69
8.8. Pharm acody namic Analysis ................................................................................................................... 69
8.9. Biomarker Analysis ................................................................................................................................ 69
8.10. Sample Size ............................................................................................................................................ 69
8.11. Data Monitoring Committee ...............................................................
................................................... 70
9. RESPONSIBILITIES ................................................................................................
.......................................... 71
9.1. Investigator Responsibilities .................................................................................................................. 71
9.1.1. Good Clinical Practice .......................................................................................................... 71
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC)/ 
Ethics Committee (EC) Review and Approval .................................................................... 71
9.1.3. Informed Consent ................................................................................................................. 71
9.1.4. Confidentiality ...................................................................................................................... 72
9.1.5. Study Files and Retention of Records .................................................................................. 72
9.1.6. Case Report Forms ............................................................................................................... 73
9.1.7. Investigational Medicinal Product Accountability and Return ............................................. 74
9.1.8. Inspections ............................................................................................................................ 74
9.1.9. Protocol Compliance ............................................................................................................ 75
9.2. Sponsor Responsibilities ........................................................................................................................ 75
9.2.1. Protocol Modifications ......................................................................................................... 75
9.2.2. Study Report and Publications ............................................................................................. 75
9.3. Joint Investiga tor/Sponsor Responsibilities ........................................................................................... 75
9.3.1. Payment Reporting ............................................................................................................... 75
9.3.2. Access to Information for Monitoring .................................................................................. 76
9.3.3. Monitoring and Oversight of Biomarker Specimens ............................................................ 76
9.3.4. Access to Information for Auditing or Inspections .............................................................. 76
9.3.5. Study Discontinuation .......................................................................................................... 76
10. REFERENCES ................................................................................................................................................... 77
11.APPENDICES .................................................................................................................................................... 80
Appendix 1. Investigator Signature Page .................................................................................................... 81
Appendix 2. Study Procedures Table for GS -US-402-1852 ....................................................................... 82
Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 86
Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing Po
tential, and 
Contraceptive Requirements ................................................................................................... 87
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 5 28June 2016LIST OF IN -TEXT TABLES
Table 1 -1. Exposure Margins for GS -9674 Based on Observed GS -9674 Exposure After 
Administration of 100 mg GS -9674 QD Under Fed Conditions at Steady -State in 
Cohort 5 Compared to Exposures Observed at NOAEL Doses in Mouse and 
Cynomolgus Monkey ............................................................................................................. 18
Table 1 -2. Preliminary Safety Summary of Subjects Following Single -and Multiple -Dose 
Administration of GS -9674 Under Fasting or Fed Conditions in Healthy Volunteers 
(GS-US- 402
-1851) ................................................................................................................. 21
Table 1 -3. Preliminary Plasma Pharmacokinetic Parameters of GS -9674 Follow ing Single -and 
Multiple
-Dose Administration of GS -9674 Under Fasting or Fed Conditions in 
Healthy Volunteers (GS -US-402-1851) ................................................................................. 23
Table 1 -4. Preliminary Pharmacodynamic Parameters (FGF19 and C4) Follow ing Multiple -
Dose Administration of Placebo, or GS -9674 Under Fasting or Fed Conditions in 
Healthy Volunteers (GS -US-402-1851) ................................................................................. 24
Table 5
-1. List of Prohibited Medications ............................................................................................... 38
LIST OF IN -TEXT FIGURES
Figure 3 -1. Overall Study Design ...............................................................
.............................................. 28
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 6 28June 2016PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Dr .
Foster City, CA 94404, U.S.A.
Study Title: A Phase 2, Randomized, Double- Blind, Placebo- Controlled Study  
Evaluating the Safet y, Tolerability, and Efficacy of GS-9674 in Subjects 
with Nona lcoholic Steatohepatitis (NASH)
IND Number:
E
udraCT Number:
Clinical Trials.gov 
Identifier:127960
2016-002496-10
TBD
Study Centers 
Planned:Approximately  50 centers in North America , Europe ,andAsia Pacific
Objectives: The primary  objective of this study  isto evaluate the safet y and 
tolerability  of GS-9674 in subjects with NASH as assessed b y magnetic 
resonance imaging -proton density  fat fraction (MRI -PDFF ) and magnetic 
resonance elastograph y (MRE) .
The exploratory  objectives of this study  are listed in Section 2.
Study Design: This is a Phase 2 ,randomized, double -blind, placebo -controlled stud y 
evaluating the safet y, tolerability, and efficacy of GS-9674 in subjects 
with NASH as assessed by MRI -PDFF and MRE .
Participation in the study can last up to 32 weeks, which includes a 
4-week screening pe riod, a 24-week treatment period during which study  
drug will be administered, and a 4 -week follow -up period. The screening 
period may  be extended under special circumstances with the explicit 
approval of the Medical Monitor.
Subjects meeting the study ’s entry criteria will be randomly  assigned in a 
2:2:1 ratio to 1 of 3 treatment groups as shown in the figure below:
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 7 28June 2016Randomization will be stratified b y the presence or absence of diabetes 
mellitus as determined by medical history, use of medication for 
indication of diabetes mellitus, or based on screening lab values if 
previously  undiagnosed (ie, hemoglobin A1c ≥ 6.5% OR fasting plasma 
glucose ≥126mg/dL).
Number of Subjects 
Planned:Approximately  125 Subjects
Target Population: Males and non -pregnant females between 18 -75 years of age without 
cirrhosis and with NASH as assessed b ymagnetic resonance imaging 
(MRI) and magnet ic resonance elastograph y (MRE).
Duration of 
Treatment:24 Weeks
Diagnosis and Main 
Eligibility  Criteria:Key inclusion and exclusion criteria are as follows :
Inclusion Criteria:
Meets all of the following conditions:
a.A clinical diagnosis of nonalcoholic fatt y liver disease (NAFLD) 
with imaging documenting fatty  liver within the past two y ears. 
If necessary  an ultrasound may  be performed during screening to 
confirm N AFLD . Note: criterion  a. must be met before 
evaluating criteria b. and c.
b.Screening MRI -PDFF with ≥10% steatosis
c.Screening MRE with liver stiffness ≥ 2.90kPa
Platelet count ≥ 100,000/mm3;
Creatinine Clearance ( CL cr) as calculated b y the Cockcroft -Gault 
equation ≥ 60 ml/min ;

GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 8 28June 2016Exclusion Criteria:
Pregnant or lactating females;
ALT > 5X ULN;
Other causes of liver disease including autoimmune, viral, and 
alcoholic liver disease;
Cirrhosis of the liver as defined b y any of the following:
a.Cirrhosis on historical liver biopsy  (eg,Brunt /Kleiner stage 4 or 
equivalent)
b.Evidence of cirrhosis on liver imaging ( eg,ultrasound, CT, or 
MRI ) including a nodular liver surface, splenomegal y, or portal 
veno us collaterals
c.Screening FibroSURE/FibroTest®≥ 0.75, as deter mined by  the 
central laboratory
d.Prior history  of decompensated liver disease, including ascites, 
hepatic encephalopath y,or variceal bleeding;
BMI < 18 kg/m2;
INR > 1.2 unless on anticoagulant t herap y;
Total bilirubin > 1x UL N, except with diagnosis of Gilbert’s 
syndrome .
Refer to Sections 4.2 and 4.3for complete listing of inclusion and 
exclusion criteria.
Study  
Procedures/
Frequency :After signing the informed consent form, subjects will complete a 
screening visit which will include the following assessments: complete 
medical history , phy sical examination (PE), vital signs, laboratory  
assessments (blood chemistry , hematology , coagulation panel, 
hemoglobin A1c, biomarkers ), viral serology , pregnancy  test (for fema les 
of child-bearing potential), standard 12- lead ECG, MRI -PDFF and MRE 
examinations, ur inedrug test, review of concomitant medications and 
adverse events.
After the screening period and a randomization visit at Baseline/ Day 1, 
study visits will occur on Weeks 1, 4, 8, 12, 16, 20 and 24 with a 
Follow -Up visit 4 weeks after the last dose of study  drug . At minimum, 
vital signs, sy mptom driven PE, safet y laboratory  tests (blood chemistry , 
hematology , and coagulation panel) , review of c oncomitant medications 
and adverse events will be done at every  visit.
Eligible subjects will be randomized to one of 3 treatment groups. Prior 
to initial dosing, required B aseline /Day 1assessments will be performed 
and will include Quality  of L ife (QoL) assessments (general and 
pruritus) , symptom driven PE, vital signs, laboratory assessments, 
pregnancy  tests (for females of child -bearing potential), urine, blood, and 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
CONFIDENTIAL Final 
Original 
stool collection for biomarker assessment, single PD sampling, standru·d 
12-lead ECG, FibroScan®, review of concomitant medications ru1d 
adverse events. 
PPD 
Subjects will return to clinic for a safety visit at Week 1. Week 1 
assessments include QoL: pmritus assessments , symptom driven PE, 
vital signs, and laboratory tests (blood chemistly , hematology , 
coagulation panel, lipid profile, biomarkers , PK and PD sampling). 
While on study, subjects will undergo the following procedmes and 
laboratmy assessments: 
• MRE and MRI-PDFF at Weeks 12 and 24 
• FibroScan® at Baseline/Day 1 and Weeks 12 and 24 
• Single PK and PD sampling at Baseline/Day 1 (PD only) and at 
Weeks 1, 4, 8, 12, 16, 20, and 24 
• Blood for Biomarkers at Baseline/Day 1, and Weeks 1, 4, 12, and 24 
• 12-lead ECGs at Baseline/Day 1, and Weeks 12 and 24 
• Blood chemistiy , hematology, coagulation panel, and fasting lipid 
profile at Baseline/Day 1 and at Weeks 1, 4, 8, 12, 16, 20, and 24 
• Hemoglobin Ale (HbA1c) at Baseline/Day 1, Weeks 12 and 24 
• Stool collection at Baseline/Day 1 and Week 24 
• Urine collection at Baseline/Day 1 and Weeks 1, 4, 12, and 24 
• Urine pregnancy test (females of childbearing potential only) at 
Baseline/Day 1 and Weeks 4, 8, 12, 16, 20, and 24 
• QoL: general assessments [SF-36 health smvey, Chronic Liver 
Disease Questionnaire (CLDQ), and Work Productivity and Activity 
Impaitment (WPAI)] at Baseline/Day 1 and Weeks 12 and 24 
• QoL: pmritus assessments (VAS-itch and 5D-itch) at Baseline/Day 1 
and Weeks 1, 4, 8, 12, 16, 20, and 24 
Subjects will return for their final visit, the Follow-Up visit, 4 Weeks 
after the last dose of study dmg. At this visit assessments include a 
symptom driven PE, vital signs, safety laboratory tests, and review of 
concomitant medications and adverse events. A urine pregnancy test will 
be perf01med for females of child bearing potential only. 
PO 
Page 9 28 June 2016 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
Test Product: PPD 
GS-9674 30 mg tablet administered orally once daily with food. 
GS-9674 100 mg tablet administe red orally once daily with food. Final 
Original 
Reference Product: Placebo-to-match (PTM) GS-9674 30 mg tablet administered orally once 
daily with food. 
Dose and Mode of 
Administration: 
Criteria for 
Evaluation: 
Safety: 
Efficacy: 
CONFIDENTIAL Placebo-to-match (PTM) GS-9674 100 mg tablet administered orally 
once daily with food. 
• Treatme nt Group A: GS-9674 30 mg (1 x 30 mg tablet)+ PTM 
GS-9674 100 mg (1 x PTM 100 mg tablet) administered orally once 
daily with food 
• Treatme nt Group B: GS-9674 100 mg (1 x 100 mg tablet)+ PTM 
GS-9674 30 mg (1 x PTM 30 mg tablet) administered orally once 
daily with food 
• Treatme nt Group C: PTM GS-9674 30 mg (1 x PTM 30 mg tablet) 
+ PTM GS-9674 100 mg (1 x PTM 100 mg tablet) administered 
orally once daily with food 
The primaty endpoint is the safety of GS-9674 in subjects with NASH. 
Safety will be assessed during the study through the repmiing of AEs, 
and by clinicallaboratmy tests and vital sign assessments at various time 
points during the study. Concomitant medication usage will also be 
assessed throughout the study. 
An independent, extemal Data Monitoring Committee (DMC) that 
consists of two hepatologists and a PhD statistician will convene once 
20 subjects have been enrolled and eve1y 3 to 4 months thereafter to 
monitor the study for safety events. The DMC will meet on an ad hoc 
basis if there are at least 3 Grade ~ 3 serious, treatment-related 
Common Terminology Criteria for Adverse Events (CTCAE) observed in 
the study. In the event of two similar Grade 4-CTCAE treatment-related 
adverse events or one Grade 5-CTCAE treatment -related adverse event, 
the DMC will review the data and advise the sponsor regm·ding stopping 
or continuing the study. 
Efficacy will be assessed through a number of exploratmy endpoints. 
These exploratmy endpoints are described in Section 8.1.3. 
Page 10 28 June 2016 
GS-9674 
Protocol GS-US-402-1852 Final 
Gilead Sciences, Inc. Original 
Phrumacokinetic and A single predose PK and PD blood srunple will be collected at each on-
Pha~mac odynamic : treatment visit for all subjects. Plasma concentrations ofGS-9674 , 
GS-716070 (metabolite ofGS-9674), and other metabolites as 
appropriate , will be determined for PK analyses as applicable. Plasma or 
semm concentrations ofFGF19, C14, and bile acids will be detetmined 
as applicable for PD analyses. 
Statistical Methods: 
Safety Analysis: 
Efficacy 
Analysis: 
Exploratmy 
Analysis: 
Srunple Size: All safety data collected will be listed and be smnmarized, as appropriate , 
by treatment group. 
The biological activi!Y of GS-9674 will be evaluated usina biomarker 
variables. PO 
PPD 
Due to the exploratmy natme of this study, no fmmal power calculations 
were used to detetmine sample size. The number of subjects was chosen 
based on clinical experience with other simila~· proof of concept studies. 
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents. 
CONFIDENTIAL Page 11 28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 12 28June 2016GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
Ab antibody
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
Apo B apolipoprotein B
aPTT activated partial thromboplastine time
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under the plasma/serum concentration versus time curve
AUC tau area under the plasma/serum concentration versus time curve over the dosing 
interval
AUC inf area under the plasma/serum concentration versus time curve extrapolated to 
infinite time, calculated as AUC 0-last+(Clast/z)
AUC partial partial area under the plasma/serum concentration versus time curve
BAP Biomarker Analysis Plan
BCRP breast cancer resistance protein
BMI body mass index
BUN blood urea nitrogen
BW body weight
C4 7-alpha -hydroxy -4
-cholesten -3-one
CBC complete blood count
cc cubic centimeter
CFR code of federal regulations
CI confidence interval
CK-18 cytokeratin 18
CL systemic clearance
CL cr creatinine clearance
CLDQ Chronic Liver Disease Questionnaire
Clast last observed quantifiable plasma/serum concentration of the drug
Cmax maximum observed plasma/serum concentration of drug
Cmin minimum observed plasma/serum concentration of drug
Ctau observed drug concentration at the end of the dosing interval
CRO contract (or clinical) research organization 
CTCAE Common Terminology Criteria for Adverse Events
CSR Clinical S tudy Report
CV cardiovascular
CYP cytochrome P450
CYP3A cytochrome P4503A
DILI drug induced liver injury
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 13 28June 2016DMC Data Monitoring Committee
DNA deoxyribonucleic acid
DSPH Drug Safety and Public Health
EC ethics committee
EC 50 concentration of drug that gives half -maximal response
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
ELF™Test enhanced liver fibrosis test
ET early termination
EU European Union
ESA erythropoiesis -stimulating agent
FAS Full Analysis S et
FDA (United States) Food and Drug Administration
FGF19 fibroblast growth factor 19
FSH follicle -stimulating hormone
FXR farnesoid X r eceptor
GCP good clinical practice
GCSF granulocyte colony stimulating factor
GGT gamma glutamyl transferase
GSI Gilead Sciences, Inc.
Hb hemoglobin
HbA1c hemoglobin A1c
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCC hepatocellular carcinoma
hCG human chorionic gonadotropin
Hct hematocrit
HCV hepatitis c virus
HDPE high-density polyethylene
HIV human immunodeficiency virus
HIV-1 human immunodeficiency virus type 1
HLT high-level term
HLGT high-level group term
HMG- CoA 3-hydroxy -3-methylglutaryl -coenzyme A
HOMA -IR homeostatic assessment of insulin resistance
IB investigator’s brochure
ICF informed consent form
ICH International Conference on Harm onization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 14 28June 2016ID identification
IEC independent ethics committee/ institutional ethics committee
IND Investigational New Drug (Application)
INR international normalized ratio
IRB institutional review board
IUD intrauterine device
IWRS interactive web response system
LDH lactate dehydrogenase
LLT lower-level term
MedDRA Medical Dictionary for Regulatory Activities
MCV mean corpuscular volume
miRNA micro ribonucleic acid
mm Hg millimeters of mercury
MRE magnetic resonance elastography
MRI magnetic resonance imaging
MRI -PDFF magnetic resonance imaging –proton density fat fraction
NAFLD nonalcoholic fatty liver disease
NAS NAFLD Activity Score
NASH nonalcoholic steatohepatitis
NMR nuclear magnetic resonance spectroscopy
NOAEL no observed adverse event level
OATP organic anion -transporting polypeptide
oz ounce 
PD pharmacodynamic
PE physical exam
PK pharmacokinetic
P-gp P-glycoprotein
pH measure of acidity 
PT preferred term
PT prothrombin time
PTM placebo -to-match
PTT partial prothrombin time
QA quality assurance
QD once a day
QoL quality of life
RBC red blood cell count
RNA ribonucleic acid
ROS reactive oxygen species
SADR serious adverse drug reaction
SAE serious adverse event
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 15 28June 2016SAP statistical analysis plan
SF-36 Short Form (36) Health Survey
SOC system organ c lass
SOP standard operating procedure
SUSAR Suspected Unexpected Serious Adverse Reaction
t1/2 An estimate of the terminal elimination half -life of the drug in 
serum/plasma/PBMC, calculated by dividing the natural log of 2 by the 
terminal elimination rate constant (λ z)
TEAE treatment -emergent adverse event
Tlast last measured concentration
Tmax time (observed time point) of C max
TGR5 bile acid receptor
TPO thrombopoietin
TR-FRET time-resolved fluorescence resonance energy transfer
UGT1A1 uridine diphosphate glucuronosyltransferase 1A1
ULN upper limit of the normal range
US United States
Vss volume of distribution
VAS visual analog scale
WBC white blood cell count
WPAI work productivity and activity impairment questionnaire
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 16 28June 20161. INTRODUCTION
1.1. Background
Chronic liver disease and the consequences of end- stage liver disease are increasing globall y 
despite improved prevention and treatment of viral hepatitis. This is due to the emerging 
epidemics of obesit y, metabolic syndrome, and diabetes mellitus that are leading to an increased 
incidence of nonalcoholic fatt y liver disease (NAFLD). Nonalcoholic fatty liver disease is 
characterized b y the excess accumulation of lipid droplets within the liver, also known as hepatic 
steatosis. Prevalence rates of NAFLD range from 6% to 37% worldwide {Vernon et al 2011 }, 
{Ong et al 2007} . Nonalc oholic steatohepatitis (NASH), an aggressive form of NAFLD 
characterized b y the presence of inflammation and hepatocellular ballooning, with or without 
fibrosis, is present in approximately  25% of patients with NAFLD. Nonalcoholic steatohepatitis 
is associ ated with increased liver- related mortalit y {Williams et al 2011 }, {Ong et al 2007 }. In the 
United States (US), it has been estimated that 3% to 6% of the population {Vernon et al 2011 }, 
{Wanless et al 1990} , or the equivalent of up to 15 million adults, have NASH. NASH represents 
a significant and growing unmet medical need for which there are no currently  approved 
therapies. Furthermore, as NASH is a manifestation of the metabolic s yndrome, risk factors for 
cardiovascular disease (eg, atherosclerotic disease, cardiac arrh ythmogenicity ) frequentl y coexist 
in the se patients {Faramawi et al 2008} , 
{Voulgari et al 2010 }, {Dietrich et al 2014} . A treatment that 
targets the underl ying metabolic disorder could potentially  ameliorate these cardiovascular risks 
and associated morbidit y and mortality.
Nonalcoholic steatohepatitis is primarily  thought to occur as the result of the metabolic 
syndrome, the impact of obesity , insulin resistance, and dy slipidemia in the liver. Simple 
steatosis is not sufficient to cause liver injury ; it is the presence of inflammation and 
hepatocellular injury  on the background of steatosis that defines NASH and results in the 
progression to end-stage liver disease and its co mplications. The “2 -hit” hypothesis of NASH 
suggests that in the setting of steatosis and metabolic dy sfunction, increased oxidative stress and 
the generation of reactive oxy gen species (ROS) likely  mediate the inflammatory  changes in the 
liver (steatohepa titis) that may  lead to progressive fibrosis {Dowman et al 2010} , {Kannel et al 
1982} , {Koek et al 2011
}, {Sumida et al 2013 }. The major pathways in NASH disease progression 
include those involved in metabolic dy sfunc tion in the hepatocy te, and activation of hepatic 
stellate cells and macrophages leading to progressive inflammation and liver fibrosis. Advanced 
fibrosis and cirrhosis are characterized b y extensive collagen deposition and remodeling of the 
extracellular matrix. In addition, evidence suggests that lipotoxic intermediates of fatt y acids 
likely  contribute to the etiology  of NASH {Neuschwander- Tetri 2010
}.
Over time, NASH may  result in progressive liver fibrosis, ultimately  leading to cirrhosis in 
10-20% of affected patients. Advanced fibrosis (bridging fibrosis or cirrhosis) is associated with 
increased morbidity  and mortality  {Ekstedt et al 2014 }, {Yeh et al 2014} . Patients with cirrhosis 
may develop hepatocellular carcinoma (HCC) and other complications of end -stage liver disease, 
including jaundice, fluid retention (edema and ascites), portal hy pertension and variceal 
bleeding, impaired coagulation an d hepatic encephalopathy . Decompensated liver disease, as 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 17 28June 2016defined b y the development of one of the above complications, has a high mortality  and the onl y 
known effective treatment is liver transplantation. With the increasing prevalence of obesit y and 
obesity-related diseases, NASH is expected to become the leading indication for liver
transplantation, and the leading etiology  of HCC among liver transplant recipients in the US 
{Wong et al 2014 }, {Afzali et al 2012 }.
1.1.1. GS-9674General Information
GS-9674 is a potent agonist of Farnesoid X Receptor (FXR) whose activity  in intestinal 
epithelial cells results in the releas e of fibroblast growth factor 19 ( FGF19). FGF19 is an 
endocrine peptide which drives a signaling cascade to decrease lipogenesis, gluconeogenesis, 
hepatic trigly ceride accumulation, and bile acid sy nthesis. Please refer to the Investigator’s 
Brochure (IB) for additional information on GS-9674, including:
In vitro FXR agonism
Nonclinical pharmacokinetics and in vitro metabolism
Nonclinical pharmacology  and toxicology
1.1.2. Nonclinical Toxicology
The nonclinical toxicity  profile of GS -9674 has been assessed in mice and cy nomolgus monkey s 
administered GS-9674 orally  for 4 weeks in both species and for 13 weeks in monkey s and 26 
weeks (in -life phase only) in mice . 
GS-9674 -related effects included non-adverse findings in the 
liver for both species that are likel y related to the pharmacology of the compound. I n both mice 
and cy nomolgus monkeys, mild increases in alkaline phosphatase ( ALP)activity , liver weight, 
and hepatocellular h ypertrophy were observed after 4 weeks of dosing. Minimal ov al cell 
hyperplasia was also observed in the liver of cy nomolgus monkey safter 4 weeks of dosing. The 
increases in AL P activity and liver weights persisted but did not progress with longer term 
dosing in monkey s (13 weeks) but the histopathological changes were no longer evident. In 
mice, the AL P activity  and liver weights were still present and were modestly  more pronounced 
with longer term dosing (26 weeks). In mice, the above findings were observed at 
≥100 mg/kg/day after 4 weeks of dosing and at all dos es (≥ 20 mg/kg/day ) after 26 weeks of 
dosing.  In monkey s, the above findings were observed at doses of 300 mg/kg/day  after both 
4
and 13 weeks of dosing. Decreases in cholesterol (≥ 60 mg/kg/day ) and trigl ycerides 
(≥ 100 mg/kg/day ) as well as increased al bumin ( ≥ 60 mg/k g/day ) observed in mice after 
4and/or 26 weeks of dosing as well as the decrease in serum bile acids (300 mg/kg/day ) in 
monkey  after 13 weeks of dosing are also likel y to be related to the pharmacology of GS-9674.
Other minimal to mild, non-adverse findings observed after 13 or 26 weeks of dosing in 
monkey s or mice, respectively , that were considered GS-9674-related included decreased red 
blood cell parameters (mouse; 
≥20 mg/kg/day ), increased platelets (mouse; 600/300 mg/kg/day ), 
shortene d activated partial thromboplastin time (monkey ; 300 mg/kg/day ), and increased 
phosphorus (mouse; 600/300 mg/kg/day ). Findings present in monkey s after 13 weeks of dosing 
were reversible after a 4 week nondosing recovery  period . In the 26 week mouse study ,there 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 18 28June 2016were no adverse findings based on the in- life data at 60 mg/kg/day ,and the no -observed -adverse 
effect level (NOAEL) in monkey s after 13 weeks of dosing was 300 mg/kg/day . 
Preliminary  steady -state PK data from Cohort 5 (administration of GS -9674 100 mg with food) 
in the ongoing Phase 1 study  of GS-
9674 ( GS-US-402- 1851: Section 1.1.5.1) indicate adequate 
safet y margins based on GS-
9674 exposures at the nonclinical NOAEL doses in mouse and 
cynomolgus monkey  (Table 1-1).
Table 1-1. Exposure Margins for GS-9674 Based on Observed GS-9674 
Exposure A fter Administration of 100mgGS-9674 Once Daily Under 
FedConditions at Steady
-State in Cohort 5 Compared 
to Exposures 
Observed at NOAEL Doses in Mouse and Cynom olgus Monkey 
SpeciesNOAEL
Exposure MarginaDose 
mg/kg/dayAUCtau
µg*hr/mL
Mouse 60b110 22
Cynomolgus Monkey 300 110 22
a Calculated using observed human AUC tauof 5.02 µg*hr/m Lat 100 mg QD dose adminis tered fed from cohort 5 in 
Study GS-US-402- 1851.
1.1.3. NonclinicalPharmacology
GS-9674 is a potent and selective agonist of FXR. This conclusion is supported by  the following 
data: 1) modeling demonstrated an interaction of GS-9674 with the binding domain of FXR 
consistent with agonist activity , 2) GS-9674 induced an agonist response in a time -resolved 
fluorescence resonance energy  transfer (TR -FRET) biochemical assay  with an EC 50of 16 nM, 
which was comparable to that of other known FXR agonists, and 3) GS-9674 did not activate the 
structurally  simi lar bile acid receptor TGR5, did not activate other nuclear hormone receptors, 
and did not bind to a panel of other off -target receptors and enzy mes.
The cellular potency  of GS-9674 to activate FXR -mediated transcription was characterized using 
a firefl y luciferase reporter gene engineered under the control of a FXR/RXR response element 
(PC-402- 2012). GS -9674 caused complete FXR activation with an EC 50value of 43 nM, which 
was more potent than chenodeox ycholic acid (EC 50of 1770 nM).
Oral dose -ranging expe riments in male cy nomolgus monkey s dem onstrated maximal increases in 
plasma FGF19 at a dose of 5 mg/kg (PC -402- 2016). In addition, the oral administration of 
GS-9674 (30 mg/kg)to cy nomolgus monkey s directly  activated intestinal FXR, as measured b y 
the exp ression of FXR -target genes in the ileum (15
-fold increase in FGF19 mRNA, and a 2 -fold 
increase in organic solute transporter (OST)α and (OST )β mRNA) (PC
-402- 2005).
The effects of GS-9674 on FGF19 levels were compared in cy nomolgus monkey s following both 
oral and intravenous (IV) administration (PC -402- 2016). Despite greater exposures following IV 
administration, only  the oral administration of GS -9674 increased circulating FGF19 levels. 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. Final 
Original 
These data suggest that intestinal FXR agonism by GS-9674 causes FGF19 production, whereas 
low systemic free drug concentrations limit effects following IV administration ofGS-9674. 
GS-9674 was evaluated in a choline-deficient high fat diet /NaN0 2 rat model of liver fibrosis 
(PC-402-2015). This in vivo model utilized "2 hits" to mimic the metabolic and oxidative stress 
components ofNASH disease in humans {Nakamoto et al2009}, {Murakami et a12013}. Treatment 
with GS-9674 dose-dependently reduced both biochemical and histological measures of liver 
fibrosis in this model. 
Safety pharmacology studies have been conducted to examine the potential effects ofGS-9674 
on the cardiovascular (CV), respiratory, and central nervous system (CNS) systems. There were 
no GS-9674-related effects on the CNS or respiratory system in mice administered up to 
600 mg/kg. In addition, there was no significant human ether-a-go-go-related gene inhibition at 
concentrations up to 100 J.lM or GS-9674-related effects on the CV system in monkeys 
administered up to 300 mg/kg. 
Overall, the results from these pharmacology studies demonstrate that GS-9674 is a potent and 
selective agonist of intestinal FXR with the potential to benefit NASH patients by inducing 
FGF19 production. 
1.1.4. Non clinical Phannacokinetics 
GS-9674 has shQwn low oral bioavailability in nonclinical species (al?proximately 10% and 20% 
when dosed as PPD j). Low, 
pH-dependent solUbility and effiux transport have been identified as factors liKely limiting 
GS-9674 absorption. 
The low systemic clearance (CL) of GS-9674 in rats, dogs and monkeys was considerably lower 
than the predicted hepatic clearance based on in vitro studies with hepatocytes. This discrepancy 
is most likely a result of protein-restricted clearance in vivo due to the very high plasma protein 
binding( > 99.6%) across species. The volume of distribution (V ss) ofGS-9674 was consistent 
with extracellular fluid (ranging from 0.16-0.21 Llkg) in rats, dogs, and monkeys. 
After oral dosing to albino and pigmented mice, C4C]GS-9674-derived radioactivity was 
distributed to most of the tissues, with the highest maximum concentrations of radioactivity 
determined in organs of absorption and excretion. Generally similar distribution patterns and 
tissue concentrations of C4C]GS-9674-derived radioactivity were observed in albino and 
pigmented mice with no observed binding to melanin. In both strains, no quantifiable 
radioactivity was detected in brain, suggesting C4C]GS-9674-derived radioactivity did not cross 
the blood: brain barrier. Fecal elimination was a predominant route of elimination of C4C]GS-9674-derived radioactivity in both mice (85. 7% and 5.45% recovered in feces and urine, 
respectively) and monkeys (78.2% and 69.7% recovered in feces in intact and bile duct 
cannulated animals) likely representing drug not absorbed from the gastrointestinal tract. 
Approximately 6% of the administered radioactivity was excreted in bile and urine in monkeys. 
Radiolabeled material was primarily excreted within the first 48 hours. 
CONFIDENTIAL Page 19 28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 20 28June 2016GS-9674 undergoes oxidative metabolism in human hepatocy tes. Comparison of metabolism in 
hepatocy tes from mice, rats, dogs, monkey s, and humans did not identify  any metabolites unique 
to humans, supporting the selection of mice and monkey s for the assessment of the toxicology  of 
GS-9674. Of the recombinant human CYP isozy mes tested, CYP2C8, CYP3A4, and CYP2C19 
were shown to metabolize GS -9674. Potent inhibitors of these CYPs therefore may  affect 
metabolism of GS -9674. GS -9674 had little inhibitory  effect on th e activities of CYP1A2, 
CYP2B6, CYP2C19 or CYP2D6 (I C50> 25 μM). For CYP2C8, CYP2C9, and CYP3A, IC 50
values of 2.4 to 13.6 μM were obtained but 
GS-9674 was not a mechanism -based inhibitor of 
these enzy mes. GS-9674 showed moderate inhibition of human UGT1A 1, sodium -taurocholate 
cotransporting poly peptide (NTCP), and bile salt export pump (I C502.8-7.7 μM). GS -9674 
inhibited human OATP1B1, OATP1B3, and OATP2B1 with I C50values of 0.68, 0.41, and 
0.21 μM, respectivel y. GS-
9674 therefore has the potential to affect hepatic/intestinal uptake of 
OATP substrates or metabolism of CYP2C8, CYP2C9, or CYP3A4 substrates when its 
concentrations are sufficiently  high. However, low solubility , high protein binding (> 99.98%) 
and low sy stemic levels reduce the potential for GS-9674 to cause drug -drug interactions via 
inhibition of metabolic enzy mes and transporters.
GS-9674 is a substrate for efflux transporters P -glycoprotein and breast cancer resistance protein , 
as well as the uptake transporters OATP1B1, 1B3, and 2B1, an d NTCP. I nhibitors or genetic 
polymorphisms affecting the activity  of these transporters may  affect GS-9674 intestinal 
absorption and hepatic uptake. This was illustrated in an in vivo study  in monkey s where 
pretreatment with cy closporin A, a known inhibit or of efflux transporters, increased the 
bioavailability  of GS-9674 approximately  5-fold.
GS-9674 is highly  selective for FXR over other nuclear hormone receptors in cell -based reporter 
assay s, including those associated with potential for induction of hum an drug metabolizing 
enzy mes and transporters (eg, pregnane X receptor, constitutive androstane receptor). Thus the 
liability  of GS-9674 to cause drug -drug interactions through proteins regulated by  these nuclear 
receptors is low.
1.1.5. Clinical Trials of GS-9674
Ongoing clinical experience with GS-9674 includes a Phase 1 clinical study  (GS-US-402- 1851). 
A brief summary  of results from this ongoing study is presented below.
1.1.5.1. GS-US-402-
1851
Study GS-US-402- 1851 is a n ongoing Phase 1, randomized, placebo -controlled, single -and 
multiple -dose study  with 4 prespecified, staggered dose -escalation cohorts and 4 randomized, 
placebo-controlled, single- and multiple -dose cohorts with adaptive dose selection and dose 
frequency .
Prelim inary  data based on an interim safet y anal ysis as of 22 June 2016 areprovided in the 
following sections. A total of 105 subjects have been randomized into 7 cohorts. One subject 
withdrew consent after randomization but prior to dosing and was not replaced . Therefore, safet y 
data described below includes 104 dosed subjects.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 21 28June 2016Subjects received single and multiple doses of GS-9674 at a dose of 10 mg QD (Cohort 1), 
30mg QD (Cohort 2), 100 mg QD (Cohort 3), or 300 mg QD (Cohort 4) administered in a 
fasting stat e, or GS-9674 100 mg QD administered in a fed state (Cohort 5), GS-9674 50 mg 
BID (Cohort 6), or 15 mg BID (Cohort 7). A summary  of treatment -emergent adverse events 
(AEs) is provided in Table 1-2. Overall, the rate of any  AEs was similar between subjects treated 
with GS-9674 or placebo. All AEs were Grade 1 or 2 in severit y; AEs occurring in greater than 
twoGS-9674 treated subjects were back pain (n =5), diarrhea (n=3), and headache (n =6).
Table 1-2. Preliminary Safety Summary of Subjects Following Single -and 
Multiple-Dose Administration of GS-9674 Under Fasting or Fed 
Conditions in Healthy Volunteers ( GS-US-
402-
1851)
Cohort 1: 
10mg 
QD 
Fasted
(N = 12)Cohort 2: 
30mg 
QD 
Fasted
(N = 12)Cohort 3: 
100mg 
QD 
Fasted
(N = 12)Cohort 4: 
300mg 
QD 
Fasted
(N = 12)Cohort 5: 
100mg   
QD    
Fed       
(N = 12)Cohort 6: 
50mg 
BID
(N = 11a)Cohort 7: 
15mg 
BID
(N = 12)Pooled 
Placebo
(N = 21)
Treatment-
Emergent 
Adverse 
Event4(33%) 3(25%) 4(33%) 3(25%) 5(42%) 3(27%) 4(33%) 5(24%)
Treatment-
Emergent 
Adverse 
Event 
Related to 
Study 
Drug0 (0%)   0 (0%) 0 (0%) 0 (0%) 1 (8%) 0 (0%) 1 (8%) 0 (0%)
Grade 3 or 
4 
Treatment-
Emergent 
Adverse 
Event0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Grade 2, 3, 
or 4 
Treatment-
Emergent 
Adverse 
Event0 (0%) 1 (8%) 1 (8%) 0 (0%) 1 (8%) 0 (0%) 0 (0%) 0 (0%)
a 1 subject withdrew consent after randomization prior to dosing and was not replaced.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 22 28June 2016Grade 2 or 3 elevations in serum alanine aminotransferase (ALT) were seen in five(6%) 
GS-9674 treated subjects and one (5%) placebo treated subject. Of these, twoGS-9674 treated 
subjects were noted to have grade 2 or 3 elevations of ALT during active treatment; one each in 
Cohort 6 ( GS-9674 50 mg BID) and Cohort 7 ( GS-9674 15 mg BID). The remaining subjects 
with elevated ALT were identified at the follow- up visit 4 day s after completing study  drug. In 
two of these subjects, elevated ALT was associated with very  high serum creatine kinase levels, 
consistent with elevation due to strenuous exercise. All ALT elevations returned to baseline and 
were not associated with changes in bilirubin or coagulation parameters. There were no clinically  
important treatment- or dose -related trends in vital signs, ECG , or ph ysical examination findings
in this study .
Preliminary  PKparameters for GS-9674 after single -and multiple -dose administration of 10, 30, 
100 or 300 mg under fasting conditions and 100 mg under fed conditions in healthy  volunteers 
are p resented inTable 1-3.GS-9674 was rapidl y absorbed with a median T maxoccurring between 
1.25 and 3.25 hours under fasting conditions. Across the dose levels tested, plasma 
concentrations declined in a bi-phasic manner with a median t 1/2of 5.56 to 12.8 hours . The lower 
observed median t1/2of 5 to 6 hours in the 10 mg and 30 mg cohorts , respectively ,may be a 
result of plasma concentrations falling below the limit of quantitation during the distributional 
phase of the profile. In general, GS-9674 AUC and C maxincreased less than dose proportionally 
above 10 mg upon single and multiple dosing. As expected based on the short GS-9674 t 1/2and 
once daily dosing, minimal to no accumulation was observed for GS-9674 AUC, C maxor C 24
from single to multiple dose ad ministration. Administration of GS-9674 with food resulted in 
prolonged absorption of GS-9674 with an approximately  60% reduction in mean C maxand 
approximately  35% reduction in mean AUC.
  Plasma concentrations of GS-716070 (a metabolite 
of GS-9674 with ~4
0-fold less potency  than GS -9674 against FXR) were analy zed in Cohort 5 
(GS-9674 100 mg administered fed).  The t 1/2of GS-716070 was similar to that of GS-9647 with 
AUC and C max~60% and 35%, respectively  of that observed for GS-9674.  Similar to GS-9674,
GS-716070 did not accumulate upon multiple dosing.  
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 23 28June 2016Table 1-3. Preliminary Plasma Pharmacokinetic Parameters of GS-9674
Following Single -and Multiple -Dose Administration of GS-9674 
Under Fasting or Fed Conditions in Healthy Volunteers 
(GS-US-
402-1851)
Parameter 
Mean (%CV)Cohort 1: 
10mg Fasted
(N = 12)Cohort 2: 
30mg Fasted
(N = 12)Cohort 3: 
100mg Fasted
(N = 12)Cohort 4: 
300mg Fasted
(N = 12)Cohort 5: 
100mg Fed
(N = 12)
Single 
DoseAUC inf 
(ng*h/ml)1260 (30.3) 2480 (37.2) 7740 (93.9) 12,500 (33.9) 5020 (40.4)
Cmax (ng/ml) 304 (41.6) 580 (48.9) 2590 (118) 3060 (66.2) 928 (58.3)
C24(ng/ml) 2.61 (49.9)b6.04 (35.7) 23.5 (40.0) 76.0 (67.4) 26.8 (42.3)
Tmax(h)a 3.00
(2.38, 4.00)3.00
(2.38, 3.63)1.75
(1.38, 2.63)1.25
(1.00, 3.13)3.75
(2.88, 4.25)
T1/2 (h)a 5.56
(5.46, 6.41)8.10
(5.74, 9.58)11.2
(8.30, 11.9)12.4
(11.4, 13.9)10.9
(8.87, 11.6)
Multiple 
DoseAUC tau 
(ng*h/ml)1280 (35.8) 2890 (23.5) 6720 (59.2) 8490 (48.8) 4180 (46.8)
Cmax (ng/ml) 322 (42.4) 718 (32.8) 2230 (75.9) 2330 (81.5) 819 (53.4)
Ctau (ng/ml) 2.75 (55.5) 7.90 (50.3) 36.3 (42.5) 70.1 (56.3) 22.6 (37.4)
Tmax(h)a 2.50
(1.50, 3.50)3.00
(1.88, 3.13)1.50
(1.00, 2.63)3.25
(1.00, 5.00)3.50
(3.00, 4.25)
T1/2 (h)a 6.75
(5.64, 8.45)5.95
(5.54, 6.55)8.99
(6.84, 11.49)12.8
(10.0, 14.7)13.1
(10.3, 15.0)
Pharmacokinetic parameters are presented as Mean (%CV), and shown to 3 significant digits 
a T maxand T 1/2 are presented as median (Q1, Q3)
b N=11
Preliminary  changes in primary  PDparameters (AUC 2-8, Cmax, and C min)determined to be the 
most sensitive measures of changes in FGF19 and C4 after multiple dose administration of 
placebo, 10, 30, 100 or 300 mg GS-9674 under fasting conditions and 100 mg under fed 
conditions in healthy  volunteers are presented in Table 1-4. In general, similar changes in PD 
parameters were observed after single or multiple dose administration (single dose data not 
shown). GS-9674 doses >30 mg significantly  increased FGF19 AUC 2-8and C maxand reduced 
C4 AUC 2-8and C max. Administration of 100 mg GS-9674 with food resulted in prolonged 
elevation of FGF19 plasma concentrations compared to administration of GS-9674 100 mg under 
fasting conditions. Across the dose range of 10 to 300 mg GS-9674 administered fasted, 
GS-9674 exposure was weakl y correlated with changes in FGF19 and moderatel y correlated with 
changes in C4 (Spearman correlation r = 0.45, p=0.002). Additionally , FGF19 and C4 AUC 2-8
changes were inversel y correlated (r = -0.335, p=0.02).
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 24 28June 2016Table 1-4. Preliminary Pharmacodynamic Parameters (FGF19 and C4)
Following Multiple -Dose Administration of Placebo, or GS-9674 
Under Fasting or Fed Conditions in Healthy Volunteers 
(GS-US-402-1851)
PD Parameter Ratio 
Compared to Day -
1
GeoMean (%CV)Placebo GS-9674
Fasted
(N=12)Fed
(N=3)10mg 
Fasted
(N=12)30mg 
Fasted
(N=12)100mg 
Fasted
(N=12)100mg 
Fed
(N=12)300mg 
Fasted
(N=12)
FGF19Day 
20AUC 2-81.35
(53.9)0.77 
(32.7)3.07
(71.9)*3.99
(42.0)*3.61
(26.9)*2.30 
(40.1)*3.94
(62.0)*
Cmax1.21
(48.0)0.73 
(45.2)2.05
(94.6)*2.39
(45.9)*2.32
(44.9)*2.24 
(31.1)*3.08
(57.0)*
C4Day 
20AUC 2-81.24
(93.8)0.98 
(41.9)0.67
(86.8)*0.39
(57.1)*0.50
(101)*0.69 
(71.3)0.33
(97.8)*
Cmin1.29
(78.7)1.08 
(42.6)0.78
(59.3)0.37
(59.6)*0.71
(72.6) *0.45 
(80.5)*0.44
(76.3)*
Pharmacodynamic parameters are presented as geometric mean ratio (arithmetic %CV), and shown to 3 significant digits
* p<0.05 compared to placebo
1.2. Rationale for This Study
Current evidence suggests that NASH is a consequence of the metabolic s yndrome with resulting 
lipotoxicity  and oxidative stress in the steatotic liver, setting off an inflammatory  response with 
subsequent activation of hepatic stel late cells and fibrogenesis. FXR agonism has been shown to 
reduce hepatic lipid synthesis and circulating triglycerides due to down regulation of SREBP- 1c, 
as well as reduce insulin resistance and hepatic gluconeogenesis. Thus GS-9674 is postulated to 
halt the instigating triggers for NASH. Animal models have demonstrated the ability  for 
GS-9674 to reverse the metabolic dy sfunction and NASH -like liver injury in a choline -deficient 
high fat diet /NaNO 2rat model of liver fibrosis. T his Phase 2 study  has been designed as a 
multicenter, randomized, double- blind, placebo- controlled study  evaluating the safet y and 
efficacy  of GS-9674 for 24 weeks in subjects with NASH. Approximately 125 NASH subjects 
without cirrhosis will be randomized in a2:2:1 ratio to receive GS-9674 at a dose of 30 mg or 
100 mg orally  QD, or placebo. Randomization will be stratified by  the presence or absence of 
diabetes mellitus, a common comorbidity  in patients with this condition.
Inclusion criteria for the stud y were developed in order to noninvasivel y identify subjects with 
NASH. Specificall y, all subjects will have a clinical diagnosis of NAFLD, evidence of ≥ 10% 
hepatic steatosis on MRI -PDFF {Bannas et al 2015 }, and increased liver stiffness on MRE 
(≥ 2.90 kPa). Previous studies have shown that patients with NAFLD and increased liver 
stiffness by  MRE have a high probability  of NASH on liver biopsy {Loomba et al 2014 }, {Chen et 
al 2011} . For example, Chen et al. reported that an MRE liver stiffness cut- off of ≥ 2.90 kPa was 
83% sensitive, 82% specific, and had an area under the receiver operating characteristic curve 
(AUROC) of 0.93 and positive predictive value of 88% for the differentiation of simple steatosis 
from NASH on biopsy . Moreover, in a meta -analy sis of MRE for the diagnosis of NAFLD -
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 25 28June 2016related fibrosis {Singh et al 2016} , a liver stiffness ≥ 2.88 kPa optimally  identified the presence of 
at least stage 1 fibrosis (AUROC 0.86). Based on these criteria, subjects enrolled in this study  
have a high probability  of NASH with fibrosis, a population with a large unmet medical need.
Since the safet y and PK of GS -9674 have not yet been e xplored in subjects with cirrhosis, 
criteria have been developed in order to exclude cirrhotic subjects based on a validated serum 
marker for fibrosis ( FibroSURE/ FibroTest®) and historical clinical, histological, and imaging 
data {Ratziu et al 2006 }.
The primary  endpoint of this study will be the safety and tolerability  of GS-9674. I n addition, the 
biological activity  of GS-9674 will be determined based on endpoints including routine liver 
biochemistry  (eg,ALT and GGT); noninvasive serum markers of liver injury  (eg,serum CK -18, 
FibroSURE/ FibroTest® and ELF™ Test); and imaging -based methods for quantify ing hepatic 
steatosis (MRI -PDFF) and fibrosis (MRE and FibroScan®). An important endpoint of interest is 
the proportion of subjects achieving ≥ 30% reduction in steatosis as assessed by  MRI -PDFF. 
This level of reduction has been associated with a significant improvement in NASH histology 
(≥ 2-point reduction in NAFLD Activity  Score) {Patel et al 2015 }
. Based on preclinical and 
clinical data, a treatment duration of 24weeks with GS -9674 is expected to be sufficient to lead 
to meaningful improvements in hepatic steatosis on MRI -PDFF and liver biochemist ry.  In 
addition to these liver
-related endpoints, the effects of GS -9674 on carboh ydrate and lipid 
metabolism ( eg,glucose, insulin, free fatt y acids, apolipoproteins, lipid profiles, and metabolites) 
will be closely  monitored in light of the mechanism of action of GS -
9674 and the importance of 
metabolic dy sfunction in contributing to the morbidity  and mortalit y (eg ,cardiovascular) of 
subjects with NASH.
This study  will evaluate the safet y, tolerability , and efficacy  of 30 mg and 100 mg GS-9674 
administered with food for 24 weeks in subjects with NASH. The doses were selected based on 
short -term safety , PK and PD 
results from S tudy GS-U S-402- 1851 in healthy  subjects. 
Across the range of GS-9674 doses evaluated (10 -300 mg QD), doses ≥30 mg provide 
comparable intestinal FXR activation assessed as increases in FGF19 exposure. Food, b y 
slowing oral absorption of GS -9674, results in prolonged elevation of plasma FGF19 
conce ntrations. Exposure -response relationships show that changes in C4 exposu re are 
negativel y correlated with changes in FGF19 exposu re as well as 
GS-9674 exposure. Based on 
these results, GS-9674 doses of 30 and 100 mg with food are selected for further study  as they  
are expected to 1) provide enteral FXR agonism and improvements in subjects with NASH and 
2) inform on the impact of increasing s ystemic GS-9674 exposure on safety  and efficacy .
In the Phase 1 stud y,GS-US-402-1851, GS -9674 was tested at doses up to 300 mg once dail y for 
up to 14 day s and was well tolerated. Taken tog ether, these data support the evaluation of 
GS-9674 30 and 100 mg in subjects with NASH .
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 26 28June 20161.3. Risk/Benefit Assessment for the Study 
This study  will provide information on the safety  and efficacy  of GS-9674 for the treatment of
patients with NASH. As there are currentl y no approved therapies for NASH, there is a large
unmet medical need for this growing population of patients.
Potential risks of a participant’s study  involvement include unknown AEs, general risks 
associated with frequent clinic visits and labora tory blood draws, and the associated pain and 
discomfort of phlebotomy. Strategies to mitigate these risks include close monitoring of lab 
values as well as AEs. 
Subjects with NASH randomized to the placebo control arm in the study  may  benefit from 
freque nt medical monitoring and close assessment of their NASH during the duration of placebo 
treatment. Subjects randomized to GS-9674 may  benefit from an improvement in their 
underly ing NASH which may  manifest as improvements in liver biochemistry , measures of 
hepatic steatosis or fibrosis, or improvements in quality  of life. Importantly, this study  will 
provide further data to info rm the clinical development of the investigational medicinal product 
GS-9674 for use in an area of unmet medical need. 
Overall, the nonclinical and limited preliminary clinical data show a positive benefit/risk ratio in 
support of the study  in subjects wi th NASH . Appropriate safety  monitoring will be conducted 
throughout the stud y to further characterize the s afety  profile of GS-9674 in NASH subjects 
without cirrhosis.
In summary , there are no approved treatment options available for patients with NASH. B ased
on past clinical experience with GS-9674, the risk/benefit is positive and supports the continued
evaluation of GS-9674 in this patient population. Data from this study  will support the
development of GS-9674
for the treatment of this condition.
1.4. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
2. OBJECTIVES 
The primary objective of this study is as follows: 
• To evaluate the safety and tolerability of GS-9674 in subjects with NASH. 
The explorator y objective s of this study are as follows: 
~ 
D 
I 
I 
I 
I 
I 
I 
I 
I 
CONFIDENTIAL Page27 -Final 
Original 
28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 28 28June 20163. STUDY DESIGN
3.1. Study Design
This is a Phase 2 ,randomize d, double -blind, placebo -controlled stud y designed to evaluate the 
safet y, tolerabilit y, and efficacy of GS-9674 in subjects with NASH .To be eligible to participate, 
subjects must have evidence of hepatic steatosis and increased liver stiffness as assesse d by 
MRI -PDFF andMRE respectivel y.Any subject with a history  of decompensated liver disease, 
including ascites, hepatic encephalopath y, or variceal bleeding will be ineligible .
The overall study  design is presented graphicall y in Figure 3-1.
Figure 3-1. Overall Study Design
3.2. Treatment Plan and Regimen
Subjects meeting the study ’s entry  criteria will be randomly  assigned in a 2:2:1 ratio to 1 of 
3different treatment groups (A, B, and C )as shown in Figure 3-1. Randomization will be 
stratified by  the presence or absence of diabetes mellitus as determined b y medical history , use 
of medication for indication of diabetes mellitus, or based on screening lab values if previousl y 
undiagnosed ( ie,hemoglobin A1c ≥ 6.5% OR fasting plasma glucose ≥ 126mg/dL).
Study  drug will be administered for a total of 24 weeks from the Baseline/Day 1visit up toand 
including the Week 24 visit. Dosage and administration of the study  drug and reference product 
are describe d in Section 5.3.

GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
3.3. Biomarker Testing 
3.3.1. Biomarker Samples to Address the Study Objectives 
Biological specimens will be collected in this stud~ er the study rocedmes table Final 
Original 
Lendix 2) PPD 
Because biomarker science is a 
.----~-~-----r ~---~~---- ~-~------~~~ rapidly evolving area of investigation, and adverse events in pmiicular are difficult to predict, it 
is not possible to specify prospectively all tests that will be done on the specimens provided. The 
biomarker tests may be modified during or after the end of the study to remove tests no longer 
indicated and/or to add new tests based upon the growing state of a1t knowledge. Samples will be 
stored for up to 15 years after the end of the study. 
Bioma1·kers testing can include circulating markers ofFXR activity such as FGF19, bile acids, 
and C4. Circulating protein markers of liver damage and inflammation , lipids, and other 
biochemicals associated with liver metabolic activity will also be measmed. Stool samples may 
be analyzed for the presence of bile acids and a smvey of potential changes in the intestinal 
microbiome dming the study. 
3.3.2. Biomarker Samples for Optional Future Research 
PD 
3.3.3. Biomarker Samples for Optional Genomic Research 
PD 
CONFIDENTIAL Page29 28 June 2016 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
p 
CONFIDENTIAL Page 30 Final 
Original 
28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 31 28June 20164. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
This study  will enroll approximately  125 subjects with nonalc oholic steatohepatitis (NASH) .
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study :
1) Males and females between 18-75 years of age; inclusive based on the date of the screening 
visit;
2) W illing and able to give informed consent prior to any stud y specific procedures being 
performed;
3) Meets all of the following conditions:
a.A clinical diagnosis of nonalcoholic fatt y liver disease (NAFLD) with imaging 
documenting fatty  liver within the past tw o years. If necessary  an ultrasound may  be 
performed during screening to confirm NAFLD . Note: c riterion a. must be met before 
evaluating criteria b. and c
.
b.Screening MRI -PDFF with ≥10% steatosis
c.Screening MRE with liver stif fness ≥ 2.90 kPa;
4) Platelet count 
≥ 100,000/mm3;
5) Creatinine Clearance ( CL cr) as calculated by  the Cockcroft -Gault equation ≥ 60 ml/min ;
6) Female subjects of childbearing potential (see definition in Appendix 4) must have a 
negative serum pregnancy  test prior to starting study  
treatment;
7) All female subjects of childbearing potential who engage in heterosexual intercourse must 
agree to use a highl y effective method of contraception during intercourse from the 
screening visit throughout the study  period and for 30 days following t he last dose of study  
drug (see Appendix 4for details) ;
8) Female subjects must refrain from egg donation or harvest during treatment and forat least
30days after last dose of study  drug;
9)
Male subjects are required to use barrier contraception (condom plus spermicide) during 
heterosexual intercourse from the screening through the study  completion and for 90 day s 
following the last dose of study  drug (see Appendix 4for details) ;
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 32 28June 201610) Male subjects must refrain from sperm donation from screening through at least 90 day s 
following the last dose of study  drug;
11) Willing and able to comply  with scheduled visits, drug administration plan, laboratory  
tests, other study  procedures, and study  restrictions;
12) Must be able to read and complete Qualit y of Life questionnaires i ndependently .
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1) Pregnant or lactating females; lactating females must agree to discontinue nursing before 
the study  drug is administered;
2) ALT >5X ULN;
3) Other causes of liver disease including autoimmune, viral, and alcoholic liver disease;
4) Cirrhosis of the liver as defined b y any of the following:
a.Cirrhosis on historical liver biopsy ( eg,Brunt /Kleiner stage 4 or equivalent)
b.Evidence of cirrhosis on liver imaging ( eg,ultrasound, CT, or MRI ) including a nodular 
liver surface, splenomegal y, or portal venous collaterals
c.Screening FibroSURE/ FibroTest®≥ 0.75, as deter mined by  the central laboratory
d.Prior history  of decompensated liver disease, includ ing ascites, hepatic encephalopath y,
or variceal bleeding;
5) History  of liver transplantation;
6) Weight reduction surgery in the past or planned during the stud y;
7) History  of intestinal resection or malabsorptive condition that may  limit the absorption of 
GS-9674. Prior cholecy stectomy  and appendectomy  are permitted.
8) BMI < 18 kg/m2;
9) INR > 1.2 unless on anticoagulant therap y;
10) Total bilirubin > 1x UL N, except with diagnosis of Gilbert’s s yndrome;
11) Chronic hepatitis B (HBsAg positive);
12) Chronic hepatitis C (HCV RNA positive);
13) HIV Ab positive;
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 33 28June 201614) Alcohol consumption greater than 21 oz/week for males or 14 oz/week for females 
(1oz/30mL  of alcohol is present in 1 12oz/360mL beer, 1 4oz/120mL  glass of wine, and a 1 
oz/30 mL measure of 40% proof alcohol);
15) Positive urine scree n for amphetamines, cocaine or opiates ( ie,heroin, morphine) at 
screening. Subjects on stable methadone or buprenorphine maintenance treatment for at 
least 6 months prior to screening may  be included in the study . Subjects with a positive 
urine drug scree n due to prescription opioid-based medication are eligible if the 
prescription and diagnosis are reviewed and approved by  the investigator;
16) Unstable cardiovascular disease as defined b y any of the following:
a.Unstable angina within 6 months prior to screeni ng
b.Myocardial infarction, coronary  artery  bypass graft surgery or coronary  angioplasty  
within 6 months prior to screening
c.Transient ischemic attack or cerebrovascular accident within 6 months prior to 
screening
d.Obstructive valvular heart disease or h ypertr ophic cardiom yopath y
e.Congestive heart failure;
17) History  of known hy percoagulable condition or prior arterial or venous thromboembolic 
disease ;
18) Use of an y prohibited concomita nt medications as described in S ection 5.5;
19) History  of a malignancy  within 5 y ears of screening with the following exceptions:
a.Adequatel y treated carcinoma in situ of the cervix
b.Adequatel y treated basal or squamous cell cancer or other localized non -melanoma skin 
cancer;
20) Any laboratory  abnormality  or condition that could , in the opinion of the investigator, 
adversel y affect the safety  of the subject or impair the assessment of study  results;
21) Participation in another investigational stud y of a drug or device within 1 month prior or 
within 5 half -lives of the prior investigational agent (wh ichever is longer) prior to 
screening;
22) Concurrent participation in another therapeutic clinical study ;
23) Known hy persensitivity  to GS-9674, the metabolites, or formulation excipient;
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 34 28June 201624) Presence of an y condition that could, in the opinion of the investigator, c ompromise the 
subject’s ability  to participate in the study , such as history  of substance abuse or a 
psychiatric (including any subjects with a ps ychiatric hospital admission or emergency  
room visit in the 2 y ears prior to screening) or medical condition;
25) Unavailable for follow -up assessment or concern for subject’s compliance with the 
protocol procedures;
26) Contraindications or inability  to complete MRI scanning ( eg,presence of permanent 
pacemakers, implanted cardiac devices, weight restrictions, etc.) .
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
5. INVESTIGATIONAL MEDICINAL PRODUCTS 
5.1. Randomization, Blinding and Treatment Codes Final 
Original 
An Interactive Web Response System (IWRS) will be used for centralized randomization and 
treatment assignment. Randomization will be stratified by the presence or absence of diabetes 
mellitus as dete1mined by medical hist01y, use of medication for indication of diabetes mellitus, 
or based on screening lab values if previously lmdiagnosed (ie, hemoglobin Ale:::: 6.5% OR 
fasting plasma glucose :::: 126 mg/d.L). 
Investigative site personnel will obtain the subject's identification number and study dmg 
assignment from the IWRS. Subjects and all personnel directly involved in the conduct of the 
study will be blinded to treatment assignment. 
Study dmg will be dispensed by the study pha1macist , or designee, in a blinded fashion to the 
subjects. 
5.1.1. Procedures for Breaking Treatment Codes 
In the event of a medical emergency where breaking the blind is required to provide medical care 
to the subject, the investigator (or designee) may obtain treatment assignment directly from the 
IWRS system for that subject (refer to the Study Reference Binder for IWRS unblinding 
instmctions). Gilead recommends but does not require that the investigator contact the Gilead 
Medical Monitor before breaking the blind. Treatment assignment should remain blinded unless 
that knowledge is necessmy to dete1mine subject emergency medical care. The rationale for 
unblinding must be clem·ly explained in somce docmnentation and on the electronic case report 
f01m ( eCRF), along with the date on which the treatment assignn1ent was obtained. The 
investigator is requested to contact the Gilead Medical Monitor promptly in case of ailY 
treatment unblinding. 
Blinding of study treatment is critical to the integrity of this clinical study and therefore, if a 
subject's treatment assignment is disclosed to the investigator , the subject will have study 
treatment discontinued. All subjects will be followed until study completion unless consent to do 
so is specifically withdrawn by the subject. 
Gilead Drug Safety and Public Health (DSPH) may independently unblind cases for expedited 
reporting of suspected lmexpected serious adverse reactions (SUSARs). 
5.2. Description and Handling of GS-9674 and PTM GS-9674 
5.2.1. Formulat ion 
GS-9674 is supplied as 30 mg a11d 100 mg strength (as free f01m equivalent) tablets. The tablets 
contain GS-967 4-02 PD D and inactive in ·edients PD 
CONFIDENTIAL Page 35 28 June 2016 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
p 
GS-9674 30 mg tablets are round, plain-faced , film-coated orange tablets and 
~~~ ~ GS-9674 100 mg tablets are capsule-shaped , plain-faced , fihn-coated orange tablets. Final 
Original 
Placebo-to-match (PTM) GS-9674 tablets are identical in size, shape, color, and appearance to 
their conesponding strengths of active GS-9674 tablets. PTM GS-9674 tablets contain the 
followin~ ·edients: PD 
5.2.2. Packaging and Labeling 
GS-9674 tablets and PTM GS-9674 tablets are packaged in white, high-density polyethylene 
(HDPE) bottles. Each bottle contains 30 tablets, a silica gel desiccant, and polyester packing 
material. Each bottle is enclosed with a white, continuous thread, child-resistant screw cap with 
an induction-sealed, ahuninum-faced liner. 
Study drug to be distributed to centers in the US and other pruiicipating countries shall be labeled 
to meet applicable requirements of the United States Food and Drug Administration (FDA), EU 
Guideline to Good Manufacturing Practice- Annex 13 (hiVestigational Medicinal Products) , 
and/or other local regulations. 
5.2.3. Storage and Handling 
GS-9674 tablets and PTM GS-9674 tablets should be stored at controlled room temperature 1mtil 
required for administration. Controlled room temperature is defined as 25°C (77°F); temperature 
excursions ru·e petmitted between 15°C and 30°C (59°F and 86°F). Storage conditions are 
specified on the label. 
Until study drug tablets are dispensed to the subjects, all bottles of study drugs should be stored 
in a securely locked area, accessible only to authorized site persollllel. To ensure the stability and 
proper identification , the drug products should not be stored in a container other than the 
container in which they were supplied. Consideration should be given to handling, preparation, 
and disposal tln·ough measures that minitnize drug contact with the body. Appropriate 
precautions should be followed to avoid direct eye contact or exposure when handling GS-9674 
tablets and PTM GS-9674 tablets. 
5.3. Dosage and Administration of GS-9674/ PTM GS-9674 
GS-9674 and GS-9674 PTM tablets will be provided by Gilead Sciences, Inc. In order to 
maintain the blind, each subject will be supplied with 2 bottles of tablets. One bottle will contain 
GS-9674 30 mg or PTM GS-9674 30 mg, the second bottle will contain GS-9674 100 mg or 
PTM GS-9674 100 mg. Dosing for each treatment group will be as follows: 
• Treatment Group A: GS-9674 30 mg (1 x 30 mg tablet)+ PTM GS-9674 100 mg (1 x PTM 
100 mg tablet) administered orally once daily with food 
CONFIDENTIAL Page 36 28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 37 28June 2016Treatment Group B: GS-9674 100 mg(1 x 100 mgtablet) + PTM GS-9674 30 mg 
(1xPTM 30 mgtablet) administered orally  once daily with food
Treatment Group C: PTM GS-9674 30 mg(1 x PTM 30 mgtablet) + PTM GS-9674 
100mg(1 x PTM 100 mgtablet) administered orally  once daily with food
The study  drug dose should be taken at approximately  the same time each day with food.
A dose will be considered missed if the subject cannot take the dose within 12 hours of their 
regular dosing time. If a subject misses a dose, the subject should take their next dose at the 
regular dosing time.
5.4. Prior and Concomitant Medications
Concomitant use of certain medications or herbal/natural supplements w ith study  drug may  result 
in PK and/or PDinteractions resulting in increases or decreases in exposure of study  drug or 
these medications. 
Concomitant medic ations taken within 30 day s of s creening through the follow -up visit need to 
be recorded in the source documents and electronic Case Report Forms (eCRFs).
Subjects with co- morbid diseases requiring medication(s) must be taking the medication(s) 
without a change in dose within 28 days of Baseline/Day 1.
5.5. Prohibited Medications
The following medications are prohibited from 28 day s prior to Baseline/Day 1up to and 
including the day  of the last dose of study  drug:
Hematologic stimulating agents ( eg,erythropoiesis -stimulating agents (ESAs); granulocy te 
colony  stimulating factor (GCSF); thrombopoietin (TPO) mimetics)
Chronic sy stemic immunosuppressants including, but not limited to, corticosteroids 
(prednisone equivalent of > 10 mg/day for > 2 weeks), azathioprine, or monoclonal 
antibodies ( eg,infliximab) . Use for <2 weeks total is allowed.
Investigational agents or devices for an y indication
Concomitant use of certain medications or herbal/natural supplements (sensitive substrates, 
inhibitors or indu
cers of drug transporters P -gp, BCRP, or OATP, or the drug metabolizing 
enzy me CYP3A or inhibitors or inducers of CYP2C8) with study  drug(s) may  result in PK 
interactions resulting in increases or decreases in exposure of study  drug(s) or concomitant 
medic ations. Examples of representative medications which are prohibited from 28 days 
prior to Baseline/ Day 1 up to and including the day  of the last dose of study  drug, are listed 
below in Table 5-1:
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 38 28June 2016Table5-1. List of Prohibited Medications
Drug Class Agents Disallowed
Antibiotics Azithromycin, Clarithromycin, Erythromycin
Acid Reducing Agents Proton -Pump Inhibitors, H2 -Receptor Antagonists, Antacidsa
Alpha 1 -Adrenoceptor Antagonists Alfuzosin
AnticonvulsantsbCarbamazepine, Clonazepam, Ethosuximide, Oxcarbazepine ,
Phenobarbital, Phenytoin
Antidiabetics Glyburide, Repaglinide
Antidepressants Trazodone
Antifungals Itraconazole, Ketoconazole , Voriconazole
Antigout Colchicine
AntimycobacterialsbRifamycins, Isoniazid
Cardiac Medications Amiodarone, Amlodipine, Bepridil, Digoxin, Diltiazem, 
Disopyramide, Dronedarone, Felodipine, Nicardipine, Nifedipine, 
Olmesartan, Ranolazine, Systemic Lidocaine, Telmisartan, 
Valsartan, Verapamil, Quinidine
Corticosteroids Dexamethasone, Fluticasone
Endothelin Receptor Antagonists Bosentan
Ergot Derivatives Dihydroergotamine, Ergonovine, Ergotamine, Methylergonovine
GI Motility Agents Cisapride
Herbal/Natural SupplementsbSt. John’s Wort, Echinaccea. Milk thistle ( ie,silymarin), Chinese 
herb sho- saiko -to (or Xiao -Shai-Hu-Tang)
HMG- CoA Reductase InhibitorscAtorvastatin, F luvastatin, Lovastatin, Pitavastatin , Pravastatin, 
Rosuvastatin , Simvastatin
Inhaled Beta Agonists Salmeterol
Phosphodiesterase Type 5 (PDE5) inhibitors Sildenafil, Tadalafil, Vardenifil
Sedatives/Hypnotics Buspirone, Clorazepate, Diazepam, Estazolam, Flurazepam, 
Midazolam, Triazolam, Zolpidem
Selective Serotonin Reuptake Inhibitors Fluvoxamine
Other Gemfibrozil, Modafinil , Sulfasalazine, Met hotrexate
a Antacids that directly neutralize stomach pH ( ie,Tums, Maalox) are permitted but may not be taken within 4 hours (before 
or after) study drug administration.
b May result in a decrease in th e concentrations of study drug .
c Use with study drug may result in an increase in the concentration of the HMG -CoA reductase inhibitors. The 28 day 
washout period does not apply to HMG-CoA reductase inhibitors, which can be taken up to the day before Baseline/Day 1.
Medications for diseas e conditions excluded from the protocol ( eg,HIV-1, HBV, or HCV
infection, active cancer, transplantation) are not listed under this prohibited medications section 
and are disallowed in the study .
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 39 28June 20165.6. Accountability forGS-9674/ PTM GS-9674 
The investigator or designee (eg, pharmacist) is responsible for ensuring adequate accountability  
of all used and unused study  drug bottles. This includes acknowledgement of receipt of each 
shipment of study  drug (quantity  and condition) , subject dispensing records, and ret urned or 
destroy ed study  product. All used and unused study  drug bottles dispensed to subjects must be 
returned to the site.
Study  drug accountability records will be provided to each stud y site to:
Record the date received and quantity  of study  drug bottl es
Record the date, subject number, subject initials, and the 
study  drug bottle number dispensed
Record the date, quantity of used and unused study  drug returned, along with the initials of 
the person recording the information.
5.6.1. I nvestigational 
Medicinal P roduct Return or Disposal
Refer to Section 9.1.7 for instructions regarding study  drug return or disposal.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 40 28June 20166. STUDY PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 2and described in the text that follows. Additional information is 
provided in the Study  Reference Binder.
The investigator must document an y deviation from protocol procedures and notify  the sponsor 
or contract research organization (CRO).
6.1. Subject Enrollme nt and Treatment Assignment
It is the responsibility  of the investigator to ensure that subjects are eligible to participate in the 
study  prior to enrollment and throughout the study . 
Documentation of the personally  signed and dated informed consent of ea ch subject, using the 
study -specific informed consent form ( ICF), is required before initiating the screening process.
After written informed consent has been obtained and eligibility  to participate established, 
investigative site personnel will obtain the subject’s identification number and study  drug 
assignment from the interactive web response s ystem ( IWRS).
6.2. Pretreatment Assessments –
Screening Visit
Subjects will be screened within 4weeks prior to randomization to determine eligibility  for 
participation in the study . The screening period may be extended under special circumstances 
with the explicit approval of the Medical Monitor.
Screening labs may  be repeated once within the screening period, pri or to administration of study  
drug to rule out laboratory  error, if any . This will be done at the discretion of the investigator and 
with prior approval of the Medical Monitor.
Subjects should be instructed to fast (no food or drink, except water), startin g from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Screening visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning.
The following will be performed and documented at S creening:
Obtain written informed consent before initiation of an y screening procedures
Review and record whether the subject meets inclusion and exclusion criteria
Obtain screening number from I WRS
Obtain medical history
Complete phy sical examination
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 41 28June 2016Record vital signs, bod y weight, and height
Obtain blood samples for :
—Chemistry
—Hematology  
—Coagulation Panel 
—Hemoglobin A1c
—Biomarkers
—HIV-1, HBV ,andHCV Serology
—Serum pregnancy  test (only  for female subjects of child bearing potential)
—Serum FSH ( only for some female subjects -seeAppendix 4) 
Conduct standard 12 -Lead ECG
Perform Ultrasound (if necessary ) for confirmation of NAFLD
Perform MRE and MRI -PDFF
Urine d rug screen for amphetamines, cocaine and opiates (ie, heroin, morphine)
Record all concomitant medic ations that the subject has taken within 30 day s prior to 
screening
Record an y serious adverse events 
and all adverse event s related to protocol mandated 
procedures occurring after signing of the consent form.
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 4weeks of the start of s creening for randomization into the study .
From the time of obtaining informed consent through the first administration of the study  drug , 
record all serious adverse events (SAEs), as well as any  adverse events related to protocol-
mandated procedures on the adverse events electronic case report form (eCRF). All other 
untoward medical occurrences observed during the screening period, includi ng exacerbation or 
changes in medical history are to be captured on the medical history  eCRF. See S ection 7
Adverse Events and Toxicity  Management for additional details.
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
6.3. Baseline/Da y 1 Randomization and Assessments Final 
Original 
Subjects retuming to the clinic for randomization at Baseline/Day I should be instructed to fast 
(no food or drink, except water), statting from midnight (00:00) or earlier, as appropriate , on the 
evening prior to the visit to ensure an approximate 8-hour fast prior to the blood sample 
collection under fasting condition the next moming. 
After review of inclusion and exclusion criteria to confilm continued eligibility, subjects will be 
randomized to study dmg assignment and receive their Subject Identification Number via the 
IWRS prior to their first dose of study drug. 
The following will be perfmmed and documented at the Baseline/Day I visit prior to dosing: 
• QoL: general assessments (CLDQ, SF-36, and WPAI) 
• QoL: pmritus assessme nts 01 AS-itch and 5D-itch) 
Note: It is recommended that QoL assessments be completed prior to any study procedures being 
performed and prior to the subject seeing a health care provider. Refer to the Study Reference 
Binder for guidance on QoL assessment administratio n. 
• Symptom driven physical examination 
• Record vital signs, waist circtm1ference, and body weight 
• Obtain blood samples for: 
-Chemistly 
- Hematology 
-Coagulation Panel 
-Lipid Profile 
- Hemoglobin A I c 
-Biomat·kers 
Single PD Sampling 
PD 
• Conduct standard I2-Lead ECG 
• Perfmm FibroScan® (if available) 
CONFIDENTIAL Page42 28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 43 28June 2016Collect urine samples for:
—Urine pregnancy  test for females of child bearing potential only
—Biomarker testing
Collect stool sample for biomarker testing
Dispense study  drug and provide subject with instruction on appropriate dosing and 
administration; 
Record all concomitant medications that the subject has taken since the previous visit
Record an y serious adverse events and all adverse events occurring since the s creening visit
Once all visit procedures have been completed, subjects will take theirBaseline/Day  1 dose of 
study  drug with food while at the investigative site.
Subjects will return to the investigative site at Week 1 (±3 day s) for a mandatory  safet y visit. 
Then, starting at the Week 4 visit, subjects will have visits every  4 weeks up to the Week 24 
visit.
6.4. Treatment Assessments
6.4.1. Week 1
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlie r, as appropriate, on the evening prior to the Week 1 visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning.
Subjects should also be instructed to HOLD their dose of study  drug on the day  of their Week 1 
visit until all visit procedures have been completed. The study  drug dose should be taken with 
food after the visit.
During the Week 1 safety visit the following will be performed and documented (±3 day s):
QoL: pruritus assessments (VAS -itch and 5D -itch)
Symptom driven phy sical examination
Record vital signs and body  weight
Obtain blood samples for:
—Chemistry
—Hematology
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 44 28June 2016—Coagulation Panel
—Lipid Profile
—Biomarkers
—Single PK and PD sampling
Collect urine sample for biomarker testing
Record all concomitant medications that the subject has taken since the previous visit
Record an y serious adverse events and all adverse events occurring since the previous visit
6.4.2. Week 4Visit
Subjects should be instructed to fast (no food or drink, except water), starting from m idnight 
(00:00) or earlier, as appropriate, on the evening prior to the Week 4 visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning.
Subjects should also be instructed to HOLD their dose of study  drug on the day  of their Week 4 
visit until all visit procedures have been completed. The study  drug dose should be taken with 
food after the visit.
The following will be performed and documented at this visit (±3 day s):
QoL: pruritus assessments (VAS -itch and 5D- itch)
Symptom driven phy sical examination
Record vital signs and body  weight
Obtain blood samples for:
—Chemistry
—Hematology
—Coagulation Panel
—Lipid Profile
—Biomarkers
—Single 
PK and PD sampling
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 45 28June 2016Collect urine samples for:
Urine pregnancy  test for females of child bearing potential only
Biomarker testing
Dispense study  drug
Record all concomitant medications that the subject has taken since the previous visit
Record an y serious adverse events and all adverse events occurring since the previous visit
6.4.3. Week 8, 16, and 20 Visits
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Week s8, 16, and 20 visits to ensure 
an approximate 8 -hour fast prior to the fasted blood sample collection the next morning.
Subjects should also be instructed to HOLD their dose of study  drug on the day  of their Weeks 8, 
16, and 20 visits until all visit procedures have been completed. The stud y drug dose should be 
taken with foo d after the visit.
The following will be performed and documented at these visits(±3 day s):
QoL: pruritus assessments (VAS -itch and 5D -itch)
Symptom driven phy sical examination
Record vital signs and body  weight
Obtain blood samples for:
—Chemistry
—Hematology
—Coagulation Panel
—Lipid Profile
—Single PK and PD 
sampling
Urine pregnancy  test for females of child bearing potential only
Dispense study  drug
Record all concomitant medications that the subject has taken since the previous visit
Record an y seri ous adverse events and all adverse events occurring since the previous visit
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 46 28June 20166.4.4. Week 12 Visit 
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Week 12 visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning.
Subjects should also be instructed to HOLD their dose of study  drug on the day  of their Week 12 
visit until all visit procedures have been completed. The study  drug dose should be taken with 
food after the visit.
The following will be performed and documented at this visit (± 7 day s):
QoL:general assessments (CLDQ, SF -36,and WAPI )
QoL: pruritus assessments ( VAS -itch and 5D -itch) 
Symptom driven phy sical examination
Record vital signs and body  weight
Obtain blood samples for:
—Chemistry
—Hematology
—Coagulation Panel
—Lipid Profil e
—Hemoglobin A1c
—Biomarkers
—Single PK and PD sampling
Collect urine samples for:
Urine pregnancy  test for females of child bearing potential only
Biomarker testing
Conduct standard 12 -Lead ECG
Perform FibroScan®(if available)
Perform MRE and MRI -PDFF
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 47 28June 2016Dispense study  drug
Record all concomitant medications that the subject has taken since the previous visit
Record an y serious adverse events and all adverse events occurring since the previous visit
6.4.5. Week 24 Visit
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Week 24 visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning.
Subjects should also be instructed to HOLD their dose of study  drug on the day  of their Week 24 
visit until all visit procedures have been completed. 
The following will be performed and documented at this visit (±7days):
QoL:general assessments (CLDQ, SF -36,and WAPI )
QoL: pruritus assessments ( VAS -itch and 5D -itch) 
Symptom driven phy sical examination
Record vital signs, waist circumference, and bod y weight
Obtain blood samples for:
—Chemistry
—Hematology
—Coagulation Panel
—Lipid Profile
—Hemoglobin A1c
—Biomarkers
—Single PK andPDsampling
Collect urine samples for:
Urine pregnancy  test for females of child bearing potential only
Biomarker testing
Conduct standard 12 -Lead ECG
Perform FibroScan®(if available)
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
• Perf01m MRE and MRI-PDFF 
• Collect stool sample for biomarkers 
• Record all concomitant medications that the subject has taken since the previous visit Final 
Original 
• Record any serious adverse events and all adverse events occmTing since the previous visit 
Once all visit procedmes have been completed , subjects will take their fmal dose of study dmg 
while at the investigative site. 
PD 
6.4.6. Unscheduled Visits 
Additiona l unscheduled assessments may be perf01med at the discretion of the investigator. 
Subjects retmning to the clinic for an unscheduled visit should be instructed to fast (no food or 
drink, except water), struiing from midnight (00:00) or earlier, as appropriate , on the evening 
prior to the visit to ensme an approximate 8-hom fast prior to the blood sample collection under 
fasting cond ition the next moming. 
Subjects should also be instmcted to HOLD their dose of study drug on the day of an 
unscheduled visit lmtil all visit procedmes have been completed. The study dmg dose should be 
taken with food after the visit. 
At a minimum , the following will be perf01med and documented. 
• Symptom driven physical exrunination 
• Record body weight 
• Obtain blood samples for: 
-Chemistly 
-Hematology 
• Record all concomitant mediations that the subject has taken since the previous visit 
• Record any serious adverse events and all adverse events occmTing since the previous visit 
If the Unscheduled visit is perf01med for the sole purpose of distt·ibution of study dmg, the 
assessments noted above do not need to be performed. 
CONFIDENTIAL Page48 28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 49 28June 20166.5. Follow-Up Visit
Subjects will return for a Follow -Up Visit four weeks after their last dose of study  drug.
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Follow -Up visit to ensure an 
approximate 8-hour fast prior to the blood sample collection under fasti ng condition the next 
morning.
The following will be performed and documented at this visit (±5days):
Symptom driven phy sical examination
Record vital signs and body  weight
Obtain blood samples for:
—Chemistry
—Hematology
—Coagulation Panel
Urine pregnancy  test for female subjects of child bearing potential onl y
Record all concomitant medications that the subject has taken since the previous visit
Record an y serious adverse events and all adverse occurring since the previous visit
6.6. Assessments for Premature Discontinuation from Study
Subjects prematurel y discontinuing from the study (for example, as a result of an AE), shoul d 
have 
an Early Termination (ET) visit, if possible, and a Follow- Up visit 4 weeks after their last 
dose of study  drug. The study  asses sments to be performed at the ET visit are the same as those 
performed at the Week 24 visit (refer to Section 6.4.5 ). The stud y assessments to be performed at 
theFollow -Up visit are listed in Section 6.5.The subject will then be withdrawn from the study .
If these visits are not possible or acceptable to the subject or investigator, the subject may  be 
withdrawn from the study. 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
6.7. Criteria for Discontinuation of Study Treatment 
Study medication may be discontinued in the following instances: Final 
Original 
• Intercunent illness that would, in the judgment of the investigator , affect assessments of 
clinical status to a significant degree. Following resolution of intercunent illness, the subject 
may resume study dosing at the discretion of the investigator. 
• Unacceptable toxicity, or toxicity that, in the judgment of the investigator , compromises the 
ability to continue study-specific procedmes or is considered to not be in the subject's best 
interest 
• Subject request to discontinue for any reason 
• Subject noncompliance 
• Pregnancy dming the study (refer to Appendix 4) 
• Sponsor discretion 
• Discontinuation of the study at the request of Gilead, a regulatoty agency or an institutional 
review board, independent ethics committee , or ethics committee (IRBIIEC/EC) 
6.8. PK and PD Substudy Visits 
PD 
CONFIDENTIAL Page 50 28 June 2016 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
6.9. Description of Assessments 
6.9.1. Clinical Laboratory Analytes 
Chemistry: Final 
Original 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, alkaline 
phosphatase (ALP), bicarbonate, blood urea nitrogen (BUN), calcium, chloride, creatinine, 
glucose, lactate dehydrogenase (LDH), magnesium, phosphorus, potassium, sodium, total and 
direct bilirubin, total protein, uric acid, gamma-glutamyl transferase (GGT). Also includes C­
Peptide and Insulin for the Baseline/Day!, Weeks 4, 12, and 24 visits. 
Creatinine clearance is calculated by the Cockcroft-Gault equation { Cockcroft et al1976} using 
actual body weight (BW). The calculation will be performed by the central laboratory. 
Hematology: 
Hematocrit (Hct), Hemoglobin (Hb ), Platelet count, Red blood cell count (RBC), White blood 
cell count (WBC) with differential (absolute and percentage) including Lymphocytes, 
Monocytes, Neutrophils, Eosinophils, and Basophils and, Reticulocyte count and mean 
corpuscular volume (MCV). 
Coagulation Panel: 
Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio 
(INR) 
Pregnancy Tests: 
Serum ~-hCG or urine ~-hCG (if positive, requires immediate confirmation with Serum ~-hCG) 
Additional Tests: 
Lipid Profile, Hemoglobin Ale, HIV-1, HBV & HCV Serology, urine drug screen (for 
amphetamines, cocaine, opiates), and genomic sample collection. 
Biomarker Tests: 
CK18 (M30 and M65), FGF-19, C4, Apolipoprotein B (Apo B), metabolite profile, bile acids, 
stool microbiome, blood miRN A, NMR lipoprofile, free fatty acids, ELF™ Test, and 
FibroSURE /Fibro Test®. 
PPD 
CONFIDENTIAL Page 51 28 June 2016 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
Phrumacokinetic CPK) and Phrumacodvnrunic CPD) Assessments 
Single PK and PD Sampling Final 
Original 
Single PK ru1d PD plasma samples will be collected and ru·chived for 1) PK analysis of GS-9674, 
GS-716070 (metabolite of GS-9674), and other metabolites as applicable, 2) to measure the 
concentration of the PD biomru·kers FGF19 and C4. 
PK and PD Substudy 
pp 
6.9.2. Medical History 
Medical histoty, induding details of illnesses and allergies, date(s) of onset, whether condition(s) 
is cunently ongoing, and medication histoty, including nicotine and alcohol use, will be 
collected for all subjects during screening. 
6.9.3. Physical Examination 
A complete physical examination should include source documentation of general appearance, 
and the following body systems: head, neck, and thyroid; eyes, ears, nose, throat, mouth, and 
tongue; chest (excluding breasts); respiratoty; cru·diovasculru·; lymph nodes; abdomen ; skin, hair, 
nails; musculoskeletal ; neurological. 
The focus of a symptom driven physical examination will be dete1mined by the investigator 
based on subject complaint. For eg, if a subject complains of a cough, a lung exam should be 
perfotmed. If consistent with pneumonia (rales/crackles on exam) then an AE would be 
documented. 
Height ~ body weight, and hip circumference will be collected at specified time points. 
6.9.4. Quality of Life (QoL) Assessme nts 
It is recommended that these questioilllaires be completed prior to the clinical and laboratoty 
assessments. The subject should read the questioilllaires by himself/herself and record the 
answers by himself/herself. 
6.9.4.1. Chronic Liver Disease Questioilllaire (CLDQ) 
The CLDQ asks 29 questions related to liver disease to measure health related quality of life in 
subjects with chronic liver disease. 
CONFIDENTIAL Page 52 28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 53 28June 20166.9.4.2. SF-36 Health Survey
The SF -36 Health Survey  asks 36 questions to measure functional health and well -being from the 
subject’s point of view and con sists of eight health domains (p hysical functioning, role- physical, 
bodily  pain, general health, vitality , social functioning, role -emotional, and mental h ealth) .These 
health domain scales contribute to the phy sical health and mental health summary  measures.
6.9.4.3. Work Productivity  and Activity  Impairment (WPAI) 
The Work Productivity  and Activity  Impairment (WPAI ) questionnaire asks 6 questions 
regarding the effect of NASH on a person’s ability to work and perform regular activities.
6.9.4.4. VAS -itch
The visual analogue scale (VAS) -itchis a tool for measuring the intensity  of pruritus.
6.9.4.5. 5- D itch
The 5 -D itch is multidimensional measure of itching that allows changes in chronic pruritus to be 
detected over time. The questionnaire measures the degree, duration, direction, disability ,and 
distribution of pruritus
.
6.9.5. Electrocardiogram
Standard 12-lead electrocardiogram (ECG) assessments will be performed. The investigator will 
review the ECGs for an y clinically  significant abnormalities to ensure subject safety . Abnormal 
ECG findings that are considered clinicall y significant b y the investigator and meet the definition 
of an AE should be reported and recorded in the AE eCRF page.
6.9.6. FibroScan®
Liver stiffness will be assessed b y FibroScan®.It is required that each subject ’sFibroScan®
assessments bedone with the same ty pe of probe at each study  visit. If FibroScan® is not 
available at a site the test may  be omitted.
Please refer to the Stud y Reference Binder for instructions on FibroScan®measurements.
6.9.7. MRE and MRI -PDFF
Liver stiffness will be assessed by  MRE and t he degree of steatosis will be measure d by 
Magnetic Resonance Imaging-Proton Densit y Fat Fraction (MRI -PDFF). Theseassessments can 
occur sequentially .
The MRE and MRI -PDFF images will be analy zedby a central reader. 
Please refer to the Study  Reference Binder for MRE and MRI -PDFF imaging guidelines.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 54 28June 20166.10. End of Study Definition
End of study  is defined as when the last patient last visit (L PLV) for the Follow -Up visit (four 
weeks after their last dose of study  drug )occurs, or the ET visit , whichever occurs later.
6.11. Post Study Care 
No post study  ongoing care will be provided.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 55 28June 20167. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product ,which does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and/or unintended sign, symptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may  also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, ov erdose, drug abuse/misuse reports, or occupational 
exposure . Preexisting events that increase in severity  or change in nature during or as a 
consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the followin g:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, andtransfusion
.
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
Screening visit that do not worsen .
Situations where an untoward medical occurrence has not occurred ( eg,hospitalization for 
elective surgery , social and/or convenience admissions) .
Overdose without clinical sequelae (see Sectio n 7.6.1 ).
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documente d on the medical history  
eCRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -
threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 56 28June 2016Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervent ion to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency  room or at home for allergic bronchospasm; blood dy scrasias or 
convulsions that do not result in hospitalization; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medi cinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to study  drug interruption, modification, or 
discontinuation mus t be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Section s 7.1.1 and 7.1.2. If the laboratory  
abnormality is part of a sy ndrome, record the s yndrome or diagnosis (eg, an emia), not the 
laboratory  result (ie, decreased hemoglobin).
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Stu dy Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to 
GS-
9674 therap y using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  othe r than the GS-9674. For 
SAEs, an alternative causality  must be provided (eg, pre -existing condition, underly ing 
disease, intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the study drug.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 57 28June 2016It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures (eg,venipun cture )
7.2.2. Assessment of Severity
The severit y grading of AEs will be assessed as Grade 1, 2, 3, 4 , or 5 according to the 
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, which can be found 
at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_8.5x11.pdf
(Appendix 3).
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory  abnormality .
The distinction between the seriousness and the severity  of an adverse event should be noted. 
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For 
example, a headache may be severe in intensity , but would not be classified as serious unless it 
met one of the criteria for serious events listed above.
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the electronic case report form (eCRF): all SAEs and adverse events 
related to protocol -mandated procedures.
Adverse Events
Following initiation of study  medication, collect a ll AEs, regardless of cause or relationship, 
until 30 day s after last administration of GS-9674; AEs must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 58 28June 2016Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur after the subject first consents to 
participate in the stud y (ie, sign sthe informed consent) and throughout the duration of the study , 
including the protocol -required post treatment follow -up period, must be reported to the eCRF 
database and Gilead Drug Safety  and Public Health (DSPH) as instructed. This also includes an y 
SAEs resulting from protocol-associated procedures performed after informed consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within 30 day s of the 
last dose of GS-9674, regardless of causality , should also be reported.
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period; 
h
owever, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of study  drug , he/she should promptly  document and 
report the event to Gilead DSPH.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline. 
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning, record t he SAE on the paper serious adv erse event reporting 
form (see Stud y Reference Binde r) and submit within 24 hours 
to:
Gilead DSPH: Fax: +1 (650) 522 -5477
Email: Safety _FC@gilead.com
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
For fatal or life -threatening events, copies of hospital case reports, autops y reports, and other 
documents are also to be s ubmitted by  e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
Additional information may be requested to ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 59 28June 20167.4. Gilead Reporting R equirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, Gile ad may  be required to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). I n accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify  worldwide regulatory  
agencies and the relevant I EC in concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by  Gilead using reference safety  
information specified in the investigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with any  study  drug . The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy . 
To minimize the possibility  of exposing stud y subjects to unusual risk, the safet y information 
from this study  will also be reviewed periodicall y by an independent Data Monitoring 
Committee (DMC). The DMC may  have access to partially  blinded or unblinded data and will
make recommendations regarding the stud y according to the DMC charter. See Section 8.11 for 
additional details regarding the DMC.
7.5. Toxicity Management 
Observation for Drug Induced Liver Injury  (DILI):
Although subjects enrolled in this study  will have baseline liver disease, their hepatic function 
should not be significantly  impaired. However, at baseline, some may  have liver biochemistry  
levels above the upper limit of normal (ULN). 
For subjects with ALT and AST below ULN at study  start, close observati on for DILI (as 
described below) should be considered in subjects with any of the following criteria (all labs 
confirmed b y repeat testing):
ALT or AST > 3 x ULN at any  time
Total bilirubin > 2 
x ULN
Alkaline phosphatase > 3 x ULN
INR >1.5 x UL N (except for subjects on anticoagulant therapy )  
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 60 28June 2016Clinical signs or symptoms that are, in the opinion of the investigator, consistent with 
hepatitis (such as right upper quadrant discomfort, fever, nausea, vomiting, jaundice, rash, or 
eosinophilia > 5%)
For subjects with ALT or AST between 1 and 5 x ULN at study  start, close observation for DILI 
(as described below) should be considered in subjects with an y of the following criteria (all labs 
confirmed b y repeat testing):
ALT or AST > 2 x baseline at an y time
Total bi lirubin > 2 x ULN  
Alkaline phosphatase > 3 x ULN
INR >1.5 x UL N (except for subjects on anticoagulant therapy )  
Clinical signs or symptoms that are, in the opinion of the investigator, consistent with 
hepatitis (such as right upper quadrant discomfort, fever, nausea, vomiting, jaundice, rash, or 
eosinophilia > 5%).  
Close observation includes:
Repeating liver biochemistries (ALT, AST, ALP, total bilirubin, I NR) within 48 hours
Obtaining a more detailed history  of symptoms and prior or concurrent disease
Obtaining a history  of concomitant drug use (including nonprescription medications and 
herbal and dietary  supplement preparations), alcohol use, recreational drug use, and special 
diets
Obtaining a history  of exposure to environmental chemical agents
Ruling out other causes of liver disease as needed (obtain viral hepatitis panel, imaging for 
evaluation of biliary  tract disease, etc. if required in the opinion of the primary  investigator)
Continue to monitor liver biochemistries twice weekly. Frequency can decrease to once a 
week or less if abnormalities stabilize or study  drug has been discontinued and subject is 
asymptomatic
During a period of close observation, study  drug can be continued, if desired, at the discretion of 
the Gilead Medical Monitor and t he principal investigator during the DILI evaluation. 
However, for all subjects, study drug should be withheld if any  of the following criteria are met:
ALT or AST > 3 x ULN AND either Total bilirubin > 2 x UL N or INR > 1.5 (in subjects not 
on anticoagula tion)
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 61 28June 2016ALT or AST > 3 x ULN AND the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
ALT or AST > 8 x ULN 
ALT or AST >5 x ULN for more than 2 weeks
AND
No other cause for the combinati on of laboratory  abnormalities is immediately  apparent ( eg,
prolonged INR with warfarin use) important potential causes or contributors to abnormal 
AST/AL T or total bilirubin values include, but are not limited to:
Obstructive gall bladder or bile duct dis ease
Viral or alcoholic hepatitis ( eg,hepatitis A/B/C/D/E, Epstein -Barr virus, 
cytomegalovirus, herpes simplex virus, varicella)
Autoimmune hepatitis
Concomitant administration of other hepatotoxins, including excessive doses of 
acetaminophen, drugs that inhibit bilirubin glucuronidation ( eg,indinavir, atazanavir, 
irinotecan), or herbal or dietary  supplements
Hypoxic or ischemic hepatopathy  or congestive hepatopathy  in association with 
significant right -sided heart failure
Wilson disease
Progression of ma lignancy  involving the liver (note that metastatic disease to the liver, by  
itself, should not be used as an explanation for significant AST/ALT elevations)
If study  drugs are withheld, they  may  be reintroduced with approval from the Medical Monitor.
Treatment -emergent toxicities will be noted by  the investigator and brought to the attention of 
the Medical Monitor. Whether or not considered treatment -related, all subjects experiencing AEs 
must be monitored periodically  until sy mptoms subside, any  abnor mal laboratory  values have 
resolved or returned to baseline levels or they  are considered irreversible, or until there is a 
satisfactory  explanation for the changes observed.
Other than in the case of the liver enzy mes noted above, Grade 3 or 4 clinically  significant 
laboratory  AEs should be confirmed by repeat testing as soon as practical to do so, and 
preferabl y within 3 calendar day s of receipt of the original test results.
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of 
the clinical severit y in the context of the underl ying conditions; this may  or may  not be in 
agreement with the grading of the laboratory  abnormality .
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 62 28June 2016Any questions regarding toxicity  management should be directed to the Medical Monitor.
7.6. Special Situations Reports
7.6.1. Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose , reports 
of AEs assoc iated with product complaints, occupational exposure with an AE, pregnancy  
reports regard less of an associated AE, and AE in an infant following exposure from 
breastfeeding.
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional andinappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labeling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot b e established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product. 
Occupational exposure is defined as exposure to a medicinal product as a result of one’s 
professional or non- professional occupation.
7.6.2. Instructions for Reporting Special Situations
7.6.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post study drug fol low-up 
period, to Gilead DSPH using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy .
Refer to S ection 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 63 28June 2016The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is alway s considered to be an SAE and w ill be reported as described in 
Sections 7.1.1 and 7.1.2. Furtherm ore, an y SAE occurring as an adverse pregnancy  outcome post 
study must be reported to Gilead DSPH .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to Gilead DSPH using the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been completed, the outcome should 
be reported directl y to Gilead DSPH. Gilead DSPH contact in formation is as follows: 
Email: Safety _FC@gilead.com and Fax: +1 (650) 522 -5477. 
Pregnancies of female partners of male stud y subjects exposed to Gilead or other study  drugs 
must also be reported and relevant information should be submitted to Gilead DSPH using the 
pregnancy  and pregnancy  outcome forms within 24 hours. Monitoring of the subject should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study  
has been completed, the outcome should be reported directl y to Gilead DSPH, fax number 
+1650 522- 5477 or email Safety _FC@gilead.com. 
Refer to 
Appendix 4for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements
.
7.6.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form a nd 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  drug and/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications.
Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a non-
Gilead concomitant medication , the AE should be reported o n the AE form . 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to S ection 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
8. STATISTICAL CONSIDERATIONS 
Details will be provided in the statistical analysis plan (SAP). 
8.1. Analysis Objectives and Endpoints 
8.1.1. Analysis Objectives 
The primary objective of this study is as follows: 
• To evaluate the safety and tolerability of GS-967 4 in subjects with NASH. 
The exploratory objectives of this study are as follows: 
~ 
0 
I 
I 
I 
I 
I 
I 
I 
I 
8.1.2. Primary Endpoint -Final 
Original 
The primaty endpoint is the safety of GS-9674 in subjects with NASH. Safety endpoints include 
extent of exposure, adverse events, and laboratmy evaluations. 
CONFIDENTIAL Page 64 28 June 2016 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
8.1.3. Exploratory Efficacy Endpoints 
PD 
I 
I 
I 
I 
I 
I 
I 
I 
I 
8.2. Analysis Conventions Final 
Original 
All individual subject data will be listed as measured. All statistical summruies and analyses will 
be perfonned using SAS® software (SAS Institute, Cmy, N01ih Cm·olina, USA). 
8.2.1. Analysis Sets 
8.2.1.1. Efficacy 
The prima1y analysis set for efficacy analysis is defined as the Full Analysis Set (F AS), which 
includes all subjects who were randomized into the study and received at least 1 dose of study 
dmg. 
Subjects who receive study dmg other than that to which they were assigned for the entire 
duration of treatment , will be analyzed according to the treatment group they were randomized 
to. 
CONFIDENTIAL Page 65 28 June 2016 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
8.2.1.2. Safety Final 
Original 
The primaty analysis set for safety analyses is defmed as all subjects who received at least 
one dose of study drug. Subjects who receive study dmg other than that to which they were 
assigned for the entire dmation of treatment, will be analyzed according to the study drug 
received. 
All data collected dming treatment plus 30 days after last dose of study drug will be included in 
the safety sUllllilaries. 
8.2.1.3. Phrumacokinetics 
There are two phrumacokinetic analysis sets: 1) The PK · Set which includes 
concentration data from the · drawn at each 
The PK Analysis Set will include all enrolled or randomized subjects who took at least one dose 
of study dmg and for whom concentration data of analytes GS-9674 (and its metabolites as 
applicable) ru·e available. The PK Analysis Set will be used for analyses of population PK. 
pp 
8.2.1.4. Phrumacodynamics 
There are two phru·macodynamic analysis sets: 1) The PD Analysis Set which includes 
concentration data from the · drawn at each visit as well 
The PD Analysis Set will include all enrolled or randomized subjects who took at least one dose 
of study dmg and for whom concentrat ion data ofFGF19, C4, and bile acids are available. The 
PD Analysis Set may be used for descriptive and/or population based PD analyses as applicable. 
PD 
8.2.1.5. Bioma1·kers 
The Biomru·ker Analysis Set will include data from subjects in the Safety Analysis Set who have 
the necessaty baseline and on-study measmements to provide interpretab le results for the 
specific paratneters of interest. 
CONFIDENTIAL Page 66 28 June 2016 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
8.2.2. Interim Analysis 
An administrative interim analysis will be perfmmed after all subjects fmish 12 weeks of 
treatment. 
8.3. Data Handling Conventions Final 
Original 
Missing data can have an impact on the inte1pretati on of the study data. In general, values for 
missing data will not be imputed. 
Where appropriate , safety data for subjects that did not complete the study will be included in 
summary statistics. For example, if a subject received study medication , the subject will be 
included in a summary of adverse events according to the treatment received; othe1wise, if the 
subject is not dosed then they will be excluded from the summa1y. If safety laboratmy results for 
a subject are missing for any reason at a time point, the subject will be excluded from the 
calculation of sUllllnaty statistics for that time point. If the subject is missing a pre-dose value, 
then the subject will be excluded from the calculation of summmy statistics for the pre-dose 
value and the change from pre-dose values. 
Values for missing safety laboratmy data will not be imputed; however, a missing baseline result 
will be replaced with a screening result, if available. If no pre-treatment laboratmy value is 
available, the baseline value will be assmned to be nmmal (ie, no grade [Grade OJ) for the 
summary of graded laboratmy abnmmalities. 
Values for missing vital signs data will not be imputed; however, a missing baseline result will 
be replaced with a screening result, if available. 
8.4. Demographic Data and Baseline Characteristics 
Demographic and baseline measurements will be summarized using standard descriptive 
methods. 
Demographic summaries will include sex, race/ethnicity, and age. 
Baseline data will include a sUllllnaty of body weight, height, body mass index, and 
randomizat ion stratification group (presence or absence of diabetes) and other disease 
characteristic vm·iables. 
8.5. Efficacy Analysis 
The biological activity ofGS-9674 will be evaluated usina radiologic endpoints and biomarker 
variables. PPD 
CONFIDENTIAL Page 67 28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 68 28June 20168.6. Safety Analysis
All safet y data collected on or after the date that GS-9674 was first dispensed up to the date of 
last dose of GS-9674 plus 30 day s will be summarized by  treatment group. Data for the 
pretreatment and follow -up periods will be included in data listings. 
8.6.1. Extent of Exposure
Data for a subject’s extent of exposure to GS-9674 will be generated from the study  drug
administration eCRF. Exposure data will be summarized by  treatment group.
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database. Adverse event severity  will be graded using the CTCAE 
Version 4.03.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
adverse event (TEAE) will be defined as 1 or both of the following:
Any AEs with an onset date on or after the study  drug start date and no later than 30 days 
after permanent discontinuation of study  drug.
Any AEs leading to premature discontinuation of study  drug.
Summaries (number and percentage of subjects) of TEAEs by  SOC and PT will be provided . 
Treatment -emergent AEs will also be summarized by  relationship to study  drug and severity . In 
addition, TEAEs leading to premature discontinuation of study  drug and study  will be 
summarized and listed.
All AEs collected during the course of the study
 will be presented in data listings with a field for 
treatment -emergent event (y es/no) . 
8.6.3. Laboratory Evaluations
Selected laboratory  data will be summarized (n, mean, SD, Median, Q1, Q3, minimum, and 
maximum) by treatment group and study  visit along with the corresponding change from 
baseline values. 
Graded laboratory  abnormalities will be defined using the grading scheme inthe CTCAE 
Version 4.03 (Appendix 3).Grading of laboratory abnormalities for anal ysispurposes will be 
performed b y the central laboratory .
Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase at least 
1 toxicity  grade from baseline at an y time post baseline up to and including the date of last dose 
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. Final 
Original 
of study dmg plus 30 days will be smnmarized by treatment group. If baseline data are missing, 
then any graded abnmmality (ie, at least a Grade 1) will be considered treatment emergent. 
8.6.4. Other Safety Evaluations 
Summaty statistics for the 12-lead ECGs petfmmed at Baseline/Day 1, Week 12, and Week 24, 
will be generated. 
8.7. Pharmacokinetic Analysis 
Plasma concentl'ations and PK parameters (eg, AUCu.u, Cmax and Ctau) will be listed and 
smnmarized as appropriate for GS-9674 (and its metabolites as applicable) using descriptive 
statistics. 
Details of the analysis plan will be provided in the Phatmacokinetic Reporting atld Analysis 
Plan. 
8.8. Pharmacodynamic Analysis 
Primary PD parameters (AUCpartiaJ, Cmax, Cmin as applicable) ofFGF19 and C4 will be listed and 
summarized as appropriate for GS-9674 using descriptive statistics. 
Details of the analysis plan will be provided in the Phatmacodynamic s Reporting and Analysis 
Plan. 
8.9. Biomarker Analysis 
Descriptive statistics of biomm·ker expression and change from baseline will be provided at each 
sampling time by treatment. Point estimates and 95% confidence intervals may be calculated. 
PD 
8.10. Sample Size 
Due to the exploratmy nature of this study, no fotmal power calculations were used to detetmine 
sample size. The number of subjects was chosen based on clinical experience with other similm· 
proof of concept studies. However , assmning that 4% of subjects in the placebo atm (N=25) and 
32% in the GS-9674 100 mg atm (N=50) have a~ 30% reduction in MRI-PDFF at 
Week 24, this sample size will provide 80% power to detect the difference based on a two-sided 
Fisher's exact test at a significance level of 0.05. 
CONFIDENTIAL Page 69 28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 70 28June 20168.11. Data Monitoring Committee
An independent, external data monitoring committee (DMC) that consists of two hepatologists 
and a PhD statistician will review the progress of the study  and perform reviews of safety  data. 
The DMC will convene once 20 subjects have been enrolled and will meet every  3 to 4 months 
thereafter to monitor the study  for safet y events. The DMC will meet on an ad hoc basis if there 
are at least 3 Grade ≥ 3 serious, treatment -related Common Terminology Criteria for Adverse 
Events (CTCAE) observed in the study . In the event of two s imilar Grade 4 -CTCAE treatment -
related adverse events or one Grade 5 -CTCAE treatment -related adverse event , the DMC will 
review the data and advise the sponsor regarding stopping or continuing the study .The DMC 
will provide recommendation to Gilead whethe r the nature, frequency , and severit y of adverse 
effects associated with study  treatment warrant the earl y termination of the study  in the best 
interests of the participants, whether the stud y should continue as planned, or the study should 
continue with m odifications. The DMC may  also provide recommendations as needed regarding 
study  design.
The DMC’s specific activities will be defined b y a mutually  agreed charter, which will define the 
DMC’s membership, conduct, and meeting schedule.
While the DMC will be asked to advise Gilead regarding future conduct of the study , including 
possible earl y study termination, Gilead retains final decision -making authority  on all aspects of 
the study .
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 71 28June 20169. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki, International Conference on Harmonisation (ICH) guidelines, or with 
the laws and regulations of the country  in which the research is c onducted, whichever affords the 
greater protection to the study  subject. These standards are consistent with the European Union 
Clinical Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply  with 21CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary  
interests in the investigational drug under stud y. This documentation must be provided prior to 
the investigator’s (and any  subinvestigat or’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of an y change in reportable interests during the stud y and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol -defined activities.
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) / 
Ethics Committee (EC) Review and 
Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC/EC .The investigator will not begin an y study subject activities 
until approval from the IRB/IEC/EC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
theIRB/IEC/EC any modifications mad e to the protocol or an y accompan ying material to be 
provided to the subject after initial IRB/IEC/EC approval, with the exception of those necessary  
to reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. The 
investigator must use the mo st current IRB/IEC/EC -approved consent form for documenting 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 72 28June 2016written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required by the 
IRB/IEC/EC or local requirements. The consent form will inform subjects about genomic testing 
and sample retention.
9.1.4. Confidentiality
The investigator must assure that subje cts’ anonymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB/IEC/EC or laboratory . Laboratory  
specimens must be labeled in such a way  as to protect subject identity  while allowing the results 
to be recorded to the proper subject. Refer to the Central Laboratory  Serv ices Manual for specific 
laboratory  instructions .NOTE : The investigator must keep a screening log showing codes, 
names, and addresses for all subjects screened and for all subjects enrolled in the study . Subject 
data will be processed in accordance with all applicable regulations .
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, eCRF , the study  drug , and any  other study  information, 
remain the sole and exclusive propert y of Gilead during the conduct of the study and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the follo wing two categories: (1) investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms,
IRB/IEC/EC and governmental approval with correspondence, informed conse nt, drug records, 
staff curriculum vitae and authorization forms, and other appropriate documents and 
correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identific ation (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 73 28June 2016Documentation of the reason(s) a consented subject is not enrolled ;
Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol ;
Start and end date (including dose regimen) of GS-9674
, including dates of dispensing and 
return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y discontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is l onger, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified by  regulatory  requirements, by  local regulations, or by an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any  clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for 
this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they  can be r eturned sealed to the investigator 
in case of a n inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an electronic case report form ( eCRF )will be completed b y an 
authorized study  staff member whose training for this function is documented according to study  
procedures. eCRF should be completed on the day of the subject visit to enable the sponsor to 
perform central monitoring of safet y data. The Eligibility  Criteria eCRF should be completed 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 74 28June 2016only after all data related to eligibility  have been received. Subsequent to data entry , a stud y 
monitor will perform source data verification within the electronic data capture ( EDC )system. 
Original entries as well as any  changes to data fields will be stored in the audit trail of the 
system. Prior to database lock (or any  interim time points as described in the clinical data 
management plan), the investigator will use his/her log in credentials to confirm that the forms 
have been reviewed, and that the entries accurately reflect the information in the source 
documents. The eCRF capture the data required per the protocol schedule of events and 
procedures. Sy stem -generated or manual queries will be issued to the investigative site staff as 
data discrepancies are identified by  the monitor or internal Gilead staff, who routinely  review the 
data for completeness, correctness, and consistency. The site coordinator is responsibl e for 
responding to the queries in a timely  manner, within the sy stem, either b y confirming the data as 
correct or updating the original entry , and providing the reason for the update ( eg,data entry  
error). At the conclusion of the study , Gilead will provide the site with a read -only archive copy  
of the data entered b y that site. This archive must be stored in accordance with the records 
retention requirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability and Return
Where poss ible, study  drug should be destroy ed at the site. If the site does not have acceptable 
procedures in place for drug destruction, arrangements will be made between the site and 
Gilead Sciences (or Gilead Sciences’ representative) for return of unused study  drug supplies.
The study  monitor will provide instructions for return.
The study  monitor will evaluate each study  center’s study  drug disposal procedures and provide 
appropriate instruction for destruction of unused study  drug supplies. If the site has an 
appropriate standard operating procedure (SOP) for drug destruction as determined by  Gilead 
QA, the site may  destro y used (empt y or partially empty) and unused study drug supplies in 
accordance with that site’s approved SOP. A cop y of the site’s approved S OP will be obtained 
for central files. 
If study  drug is destro yed on site, the investigator must maintain accurate records for all study  
drug destroy ed. Records must show the identification and quantity  of each unit destroy ed, the 
method of destruction, and the person who disposed of the study  drug . Upon study  completion, 
copies of the study  drug accountability  records must be filed at the site . Another cop y will be 
returned to Gilead. Refer to the Pharmacy  
Binder for study  drug disposal/return instructions.
The study  monitor will review study  drug supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make avai lable all source documents and other records for this 
study to 
Gilead’s appointed stud y monitors , the IRB/IEC/EC ,or to regulatory  authority  or health 
authority  inspectors.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 75 28June 20169.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is condu cted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit a ll protocol modifications to the IRB/IEC/EC
in accordance with local requirements and receive documented IRB/ IEC/EC approval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) willbe prepared and provided to the regulatory agenc ies.Gilead 
will ensure that the report meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certa in cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met : the results of the stud y 
in their entiret y have been publicly disclosed b y or with the consent of Gilead in an abstract, 
manuscript, or presentation form or the stud y has been completed at all study sites for at least 2 
years.
The investigator will submit to Gilead any  proposed publication or presentation along with the 
respecti ve scientific journal or presentation forum at least 30 days before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protectio n if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, eg, attendance at I nvestigator's Meetings.  If required under the appli cable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 76 28June 2016expenses paid or reimbursed for such services, including an y clinical study payments, meal, 
travel expenses or reimbursements, consulting fees, and an y other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the
eCRF .
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have a ccess to an y subject records needed to 
verify  the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected through an y type of monitoring (central, on site) are resolved.
9.3.3. Monitoring and Oversight of Bi omarker Specimens 
Biomarker research specimens will be tracked in a manner consistent with Good Clinical 
Practice b y a quality -controlled, auditable, and appropriatel y validated laboratory information 
management s ystem, to ensure compliance with data conf identialit y as well as adherence to 
authorized use of specimens as specified in this protocol and in the Informed Consent Form.  
9.3.4. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.5. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs/IECs/ECs . In terminating the study , Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subject s’ interests.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 77 28June 201610. REFERENCES
Afzali A, Berry  K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic 
steatohepatitis in the United States. L iver Transpl 2012;18 (1):29 -37.
Bannas P, Kramer H, Hernando D, Agni R, Cunningham AM, Mandal R, et al. Quantitative 
magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human 
livers. Hepatology  2015;62 (5):1444-55.
Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL . Early detection of 
nonalcoholic steatohepatitis in patients with nonalcoholic fatt y liver disease by 
using MR elastograph y. Radiology  2011;259 (3):749-56.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Dietrich P, Hel lerbrand C. Non- alcoholic fatt y liver disease, obesity and the metabolic s yndrome. 
Best practice & research 2014;28 (4):637-53.
Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non -alcoholic fatty  liver disease. 
QJM 2010;103 (2):71-83.
Ekstedt M, Hagst rom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the 
strongest predictor for disease -specific mortality  in NAFLD after up to 33 y ears 
of follow -up [Accepted Article]. Hepatology  2014.
Faramawi MF, Wildman RP, Gustat J, Rice J, Abd ul Kareem MY. The association of the 
metabolic sy ndrome with QTc interval in NHANES III. Eur J Epidemiol 2008;23 
(7):459-65.
Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial 
fibrillation: the Framingham study . N Engl J Med 1982;306 (17):1018 -22.
Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non -alcoholic steatohepatitis. Clin 
Chim Acta 2011;412 (15- 16):1297-305.
Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance 
elastograph y predicts advanced fibrosis in patients with nonalcoholic fatt y liver 
disease: a prospective study . Hepatology  2014;60 (6):1920 -8.
Murakami S, Takay ama F, Egashira T, Imao M, Mori A. Fermented papay a preparation halts the 
progression of non- alcoholic steatohepatitis in rats. Journal of Biophy sical 
Chemisty  2013;4 (2):84-90.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 78 28June 2016Nakamoto K, Takay ama F, Mankura M, Hidaka Y, Egashira T, Ogino T, et al. Beneficial Effects 
of Fermented Green Tea Extract in a Rat Model of Non -alcoholic Steatohepatitis. 
Journal o f clinical biochemistry  and nutrition 2009;44 (3):239-46.
Neuschwander -Tetri BA. Hepatic lipotoxicity  and the pathogenesis of nonalcoholic 
steatohepatitis: the central role of nontrigl yceride fatty  acid metabolites. 
Hepatology  2010;52 (2):774-88.
Ong JP, Y ounossi ZM. Epidemiology  and natural history  of NAFLD and NASH. Clin L iver Dis 
2007;11 (1):1 -16, vii.
Patel JR, Bettencourt R, Cui JY, Salotti J, Hooker J, Bhatt A, et al. Non -invasive quantitative 
decline in liver fat content on MRI  and histologic response in nonalcoholic 
steatohepatitis: A secondary  anal ysis of MOZART trial [Abstract 913]. American 
Assoication for the Study of L iver Diseases (AASLD); 2015 13 -17 November; 
San Francisco, CA. pp. 659A -60A.
Ratziu V, Thibault V, Benhamou Y, Poy nard T. Success ful rescue therap y with tenofovir in a 
patient with hepatic decompensation and adefovir resistant HBV mutant. Comp 
Hepatol 2006;5:1.
Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, et al. Magnetic resonance 
elastograph y for staging liver fibrosi s in non- alcoholic fatty  liver disease: a 
diagnostic accuracy  systematic review and individual participant data pooled 
analysis. European radiology  2016;26 (5):1431 -40.
Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stre ss in 
NAFLD/NASH. Free radical research 2013;47 (11):869 -80.
Vernon G, Baranova A, Younossi ZM. S ystematic review: the epidemiology  and natural history  
of non- alcoholic fatty  liver disease and non -alcoholic steatohepatitis in adults. 
Aliment Pharmacol Ther 2011;34 (3):274 -85.
Voulgari C, Tentolouris N, Papadogiannis D, Moyssakis I, Perrea D, Ky riaki D, et al. Increased 
left ventricular arrh ythmogenicity  in metabolic s yndrome and relationship with 
myocardial performance, risk factors for atherosclerosis, and low-grade 
inflammation. Metabolism: clinical and experimental 2010;59 (2):159 -65.
Wanless I R, Lentz JS. Fatty  liver hepatitis (steatohepatitis) and obesity : an autopsy  study  with 
analysis of risk factors. Hepatology  1990;12 (5):1106-10.
Williams CD, Steng el J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of 
nonalcoholic fatt y liver disease and nonalcoholic steatohepatitis among a largely 
middle -aged population utilizing ultrasound and liver biopsy : a prospective study . 
Gastroenterology  2011; 140 (1):124-31.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 79 28June 2016Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly  growing 
indication for liver transplantation in patients with hepatocellular carcinoma in the 
U.S. Hepatology  2014;59 (6):2188-95.
Yeh MM, Brunt EM. Pathological f eatures of fatty  liver disease. Gastroenterology  2014;147 
(4):754-64.
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 80 28June 201611. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table for GS -US-402-1852
Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
GS-9674 
Protocol GS-US-402-1852 Final 
Gilead Sciences, Inc. Original 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES , INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
U.S.A. 
STUDY ACKNOWLEDGEM ENT 
A Phase 2, Randomized , Double-Blind, Placebo-Controlled Study Evaluating the Safety, 
Tolerability , and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis 
(NASH) 
GS-US-402-1852 Original Protocol, 28 June 2016 
This protocol has been approved by Gilead Sciences, Inc. The following signature document s 
this approval. PPD 
INVESTIGATOR STATEMENT 
1 have read the protocol, including all appendice s, and I agree that it contains all necessary 
details tor me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
1 will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this marerial with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) Signature 
Date S1te Number 
CONFIDENTIAL Page 81 28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 82 28June 2016Appendix 2. Study Procedures Table for GS-US-402-1852
Screening Treatment Follow-Up
Unscheduled 
VisityWeek -4
to Day 0aBaseline/
Day 1Week 1
± 3 daysWeek 4
± 3 daysWeek 8
± 3 daysWeek 12
± 7 daysWeek 16
± 3 daysWeek 20
± 3 daysWeek 24/ ETb
± 7 daysFollow-Upb
± 5 days
Subject FastingcX X X X X X X X X X X
Written Informed 
ConsentdX
Revie w 
Inclusion/Exclusion 
CriteriaX X
Medical History X
QoL: General 
Assessments (CLDQ , 
SF-36, and WPAI)eX X X
QoL: Pruritus 
Assessments ( VAS -
itch and 5D -itch)eX X X X X X X X
Com plete Physical 
ExaminationX
Symptom Driven 
Physical ExaminationfX X X X X X X X X X
Vital SignsgX X X X X X X X X X
WeighthX XiX X X X X X XiX X
Height X
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sc iences, Inc. Original
CONFIDENTIAL Page 83 28June 2016Screening Treatment Follow-Up
Unscheduled 
VisityWeek -4
to Day 0aBaseline/
Day 1Week 1
± 3 daysWeek 4
± 3 daysWeek 8
± 3 daysWeek 12
± 7 daysWeek 16
± 3 daysWeek 20
± 3 daysWeek 24/ ETb
± 7 daysFollow-Upb
± 5 days
ChemistryjX X X X X X X X X X X
Hem atologykX X X X X X X X X X X
Coagulation PanellX X X X X X X X X X
Lipid Profile X X X X X X X X
Hem oglobin A1c X X X X
Blood for 
BiomarkersmX X X X X X
Single PKand PD
SamplingXnX X X X X X X
HIV-1, HBV and
HCV SerologyX
Pregnancy TestoX X X X X X X X X
Serum FSHpX
Genomic SampleqX
12-lead ECG X X X X
UltrasoundrXr
FibroScan®sX X X
MREtX X X
MRI -PDFFtX X X
Urine Drug ScreenuX
GS-9674 
Protocol GS-US-402-1852 
Gilead Sciences, Inc. 
Screening 
Week -4 
toDay Oa 
Urine Collection for 
(Biomarker) 
Stool Collection for 
(Biomarker) Fp-o 
Dispense GS-9674 
and PTM GS-9674w 
Concomitant X 
Medications 
Adverse Events X 
Take GS-9674/ PTM 
GS-9674 Tabletsx Baseline/ Weekl 
Day 1 ± 3 days 
X X 
X 
X 
X X 
X X Treatment 
Week4 WeekS Week12 Week16 
± 3 days ± 3 days ± 7 days ± 3 days 
X X 
X X X X 
X X X X 
X X X X 
X-Daily (Baseline / Day 1 to Week 24) Week20 Week24/ETb 
± 3 days ± 7 days 
X 
X 
X 
X X 
X X Follow-Up 
Follow-Uph 
± 5 days 
X 
X Final 
Original 
Unscheduled 
VisifY 
X X 
a. The screening visit window may be extended nnder special circumstances with explicit approval of the Medical Monitor. Subjects who fail to meet eligibility criteria due to 
an abnormal laboratory result may nndergo re-testing of the abnormal analyte during the screening window. This will be done at the discretion of the investigator and with 
prior approval of the Medical Monitor. 
b. Subjects discontinuing the study at any time for any reason (Early Termination- ET) should complete the procedures listed for the Week 24/ET Visit AND the Follow-Up 
visit. 
c. Subjects must be in a fasted state for at least 8 hours prior to blood collection . 
d. Obtain written informed consent before initiation of any screening procedure. 
e. It is recommended that QoL assessments be completed prior to any study procedures being performed and prior to the subject seeing a health care provider. Refer to the Study 
Reference Binder for guidance on QoL assessment administration. 
f. The focus of a symptom driven physical examination will be determined by the investigator based on subject complaint. 
g. Vital signs include blood pressure, heart rate, respiration rate, and body temperature. 
h. Refer to the Study Reference Binder for specific instructions on how weight should be measured. 
1. During the Baseline/Day 1 and Week 24 visits, measurements of waist circumference should be performed. Refer to the Study Reference Binder for specific instructions on 
how these measurements are to be done. 
CONFIDENTIAL Page 84 28 June 2016 I 
GS-9674 
Protocol GS-US-4 02-1852 
Gilead Sciences, Inc. Final 
Original 
J. Blood chemistry will include: alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, alkaline phosphatase, bicarbonate, blood urea nitrogen (BUN), 
calcium, chloride, creatinine, glucose, lactate dehydrogenase (LDH), magnesium, phosphorus, potassium, sodium, total and direct bilirubin, total protein, uric acid, gamrna­
glutamyl transferase ( GGT). Also includes C-Peptide and Insulin for the Baseline/Day 1, Week 4, 12, and 24 visits. 
k. 
l. Hematology will include: complete blood cell count with differential (red blood cells, white blood cells, platelets, and hematocrit). 
Coagulation Panel includes: PT, PTT, and INR. 
m. PPD 
n. 
0. 
p. 
q. 
r. PD samplmg oi1ly at BaselllielDay . 
Females of childbearing potential only (see Appendix 4). Serum pregnancy test at Screening and Urine pregnancy test at all other visits, except Week 1. 
Only required for some female subjects- see Appendix 4. 
P~D ~----~----------------------------------------------~ 
~Itrasouna may be pertormedl.f necessary to conimn1\J"XFLD-. ------------------------------' 
S. Subject should be in fasted state for Fibroscan collection. Refer to the Study Reference Binder for further details. If FibroScan'~"'is not available at a site the test may be 
omitted. 
t. Subjects should be in fasted state for MRE/MRI-PDFF exams. Refer to the Study Reference Binder for further details. Subject must have confirmed NAFLD before 
MRE/MRI-PDFF exams are done. 
u. Drug screen for amphetamines, cocaine, and opiates (ie, heroin, morphine). 
v. PPD 
w. StudychUg wiffbe assignedvia fueiWRS system every 4 weeKs from Baseline/Day 1 through Week 20. 
x. Subjects will self-administer the study drug at the investigative site at the conclusion of the Baseline/Day 1 and Week 24 visits. 
y. If the Unscheduled visit is performed for the sole purpose of distribution of study drug, the assessments noted for this visit do not need to be performed. 
CONFIDENTIAL Page 85 28 June 2016 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 86 28June 2016Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory 
Abnormalities
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_8.5x11.pdf
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 87 28June 2016Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically  documented ovarian failure.
Women are considered to be in a postmenopausal state when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
b.Definition of Male Fe rtility
For the purposes of this study , a male born subject is considered fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchidectomy or medical documentation.
2)Contraception Requirements for Female Subjects
a.Study Drug Effec ts on Pregnancy and Hormonal Contraception
The risks of treatment with GS-9674 during pregnancy  have not been evaluated. There are no 
pre-clinical data available to determine whether GS-9674 is teratogenic or fetotoxic in early  
human pregnancy . Pregnancy  must therefore be excluded before the start of treatment with study  
drug and prevented thereafter b y reliable, highl y effective contraceptive methods. Pregnancy 
tests will be performed regularl y throughout this study. Please refer to the latest version of t he 
investigator’s brochure for additional information.
Drug -drug interaction (DDI) with hormones used for contraception is not available. There are 
insufficient data to exclude the possibility  of a clinically  relevant interaction between GS -
9674 
and hormonal contraceptives that result in reduced contraception efficacy . Therefore, the use of 
hormonal contraception with GS-
9674 is not recommended.
b.Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures. They  must also not rely  on hormone -containing contraceptives as a form 
of birth control during the study . They  must have a negative seru m pregnancy  test at Screening 
and a negative pregnancy test on the Baseline/Day 1visit p rior to randomization. Pregnancy  tests 
GS-9674
Protocol GS -US-402-1852 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 88 28June 2016will be performed at monthly  intervals thereafter. Female subjects must agree to one of the 
following from Screening until 30 da ys following the last dose of the stud y drug, GS-9674.
Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consiste nt and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Tubal sterilization
Essure micro- insert sy stem (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 day s after the last dose of the study  drug, GS -
9674.
3) Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s semin al fluid. Therefore, male subjects with female 
partners of childbearing potential must use condoms (plus spermicide) during treatment and until 
90 day s after the last dose of GS-9674. 
Additional contraception recommendations should also 
be considered if th e female partner is not pregnant.
Male subjects must also refrain from sperm donation during treatment and until at least 90 day s 
after the last dose of the study  drug, GS -
9674.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence ( eg,calendar, ovulati on, 
symptothermal, post
ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenorrhea method (LAM). Female condom and male condom should not be used 
together.
5)Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 30days(or 90 day s for the partner of male subjects)
of last study  drug dose .Subjects who become pregnant or who suspect that they  are pregnant 
during the stud y must report the information to the investigator and discontinue study drug 
immediately . Subjects whose partner has become pregnant or suspects she is pregnant during the 
study  must report the information to the investigator. I nstructions for reporting pregnancy , 
partner pregnancy , and pregnancy  outcome are outlined in Section 7.6.2.1.